S. Verstovsek

H. Deeg, J. Radich, N. Kröger, 2014, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Ruxolitinib: Long-Term Management of Patients with Myelofibrosis and Future Directions in the Treatment of Myeloproliferative Neoplasms

S. Verstovsek, A. Yacoub, O. Odenike, 2014, Current Hematologic Malignancy Reports.

Modest activity of pomalidomide in patients with myelofibrosis and significant anemia.

M. Konopleva, H. Kantarjian, J. Cortes, 2013, Leukemia research.

Interim analysis of safety and efficacy of ruxolitinib in patients with myelofibrosis and low platelet counts

H. Kantarjian, S. Verstovsek, R. Paquette, 2013, Journal of Hematology & Oncology.

Single agent bevacizumab for myelofibrosis: results of the Myeloproliferative Disorders Research Consortium Trial

S. Verstovsek, R. Hoffman, R. Mesa, 2013, Haematologica.

Prognostic model to identify patients with myelofibrosis at the highest risk of transformation to acute myeloid leukemia.

H. Kantarjian, J. Cortes, A. Quintás-Cardama, 2013, Clinical lymphoma, myeloma & leukemia.

Emerging drugs for myelofibrosis

S. Verstovsek, E. Atallah, 2012, Expert opinion on emerging drugs.

Advances in the management of myelofibrosis.

S. Verstovsek, E. Padron, A. List, 2012, Cancer control : journal of the Moffitt Cancer Center.

Advances in the Management of Myelofi brosis

S. Verstovsek, E. Padron, A. List, 2012 .

Spleen deflation and beyond: The pros and cons of Janus kinase 2 inhibitor therapy for patients with myeloproliferative neoplasms

A. Quintás-Cardama, S. Verstovsek, A. Quintás-Cardama, 2012, Cancer.

Comparison of thalidomide and lenalidomide as therapy for myelofibrosis.

H. Kantarjian, J. Cortes, S. Verstovsek, 2011, Blood.

Janus kinase inhibitors for the treatment of myeloproliferative neoplasias and beyond

H. Kantarjian, J. Cortes, A. Quintás-Cardama, 2011, Nature Reviews Drug Discovery.

The role of cytogenetic abnormalities as a prognostic marker in primary myelofibrosis: applicability at the time of diagnosis and later during disease course.

H. Kantarjian, J. Cortes, S. Verstovsek, 2009, Blood.

Phase III MANIFEST-2: pelabresib + ruxolitinib vs placebo + ruxolitinib in JAK inhibitor treatment-naive myelofibrosis.

A. Mead, S. Verstovsek, M. Talpaz, 2022, Future oncology.

SOHO State of the Art Updates and Next Questions: Novel Therapies in Development for Myelofibrosis.

S. Verstovsek, N. Pemmaraju, L. Masarová, 2021, Clinical lymphoma, myeloma & leukemia.

Paradigm shift: combination BET and JAK inhibition in myelofibrosis

S. Verstovsek, J. Mascarenhas, A. Gerds, 2021, Leukemia.

Management of myelofibrosis after ruxolitinib failure

S. Verstovsek, P. Bose, 2020, Leukemia & lymphoma.

Long-term effects of ruxolitinib versus best available therapy on bone marrow fibrosis in patients with myelofibrosis

H. Kantarjian, J. Cortes, S. Verstovsek, 2018, Journal of Hematology & Oncology.

Clonal evolution and outcomes in myelofibrosis after ruxolitinib discontinuation.

H. Kantarjian, T. Manshouri, S. Verstovsek, 2017, Blood.

Developmental Therapeutics in Myeloproliferative Neoplasms

S. Verstovsek, P. Bose, 2017, Clinical lymphoma, myeloma & leukemia.

MYELOID NEOPLASIA Correlation of mutation pro ﬁ le and response in patients with myelo ﬁ brosis treated with ruxolitinib

H. Kantarjian, J. Cortes, T. Manshouri, 2015 .

Tips on using ruxolitinib in everyday practice as therapy for myelofibrosis

S. Verstovsek, 2014, Leukemia & lymphoma.

Ruxolitinib: An Oral Janus Kinase 1 and Janus Kinase 2 Inhibitor in the Management of Myelofibrosis

S. Verstovsek, 2013, Postgraduate medicine.

Therapeutic effects of ruxolitinib in patients with myelofibrosis without clinically significant splenomegaly.

Z. Estrov, H. Kantarjian, S. Verstovsek, 2012, Blood.

Comparison of the Efficacy of Placebo and Best Available Therapy for the Treatment of Myelofibrosis in the COMFORT Studies

S. Verstovsek, R. Mesa, C. Harrison, 2011 .

Evaluating the serial use of the myelofibrosis symptom assessment form for measuring symptomatic improvement

Z. Estrov, H. Kantarjian, J. Cortes, 2011, Cancer.

The Burden of Fatigue and Quality of Life in Myeloproliferative Disorders (MPDs): An International Internet Based Survey of 1179 MPD Patients.

J. Sloan, H. Kantarjian, S. Verstovsek, 2006 .

Efficacy and safety of intravenous voriconazole and intravenous itraconazole for antifungal prophylaxis in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome

H. Kantarjian, J. Cortes, S. Verstovsek, 2009, Supportive Care in Cancer.

The effect of long-term ruxolitinib treatment on JAK2p.V617F allele burden in patients with myelofibrosis.

J. Radich, S. Verstovsek, M. Deininger, 2015, Blood.

JAK2V617F complete molecular remission in polycythemia vera/essential thrombocythemia patients treated with ruxolitinib.

S. Verstovsek, P. Guglielmelli, A. Pancrazzi, 2015, Blood.

NCCN Guidelines Insights: Myeloproliferative Neoplasms, Version 2.2018.

E. Ranheim, K. Gregory, C. Fletcher, 2017, Journal of the National Comprehensive Cancer Network : JNCCN.

Phase II Study of Low-Dose Pomalidomide in Patients with Myelofibrosis and Significant Anemia (hemoglobin <10g/dL)

H. Kantarjian, J. Cortes, S. Verstovsek, 2011 .

Comparison of Outcomes of Advanced Myelofibrosis Patients Treated with Ruxolitinib (INCB018424) to Those of a Historical Control Group: Survival Advantage of Ruxolitinib Therapy

M. Cazzola, Z. Estrov, H. Kantarjian, 2011 .

Dynamics of Mutant Alleles in Patients with Advanced Essential Thrombocythemia (ET) or Polycythemia (PV) During Pegylated Interferon-Alfa-2A (PEG-IFN-α-2A; Pegasys) Therapy

O. Abdel-Wahab, R. Levine, H. Kantarjian, 2011 .

Consistent Benefit of Ruxolitinib Over Placebo in Spleen Volume Reduction and Symptom Improvement Across Subgroups and Overall Survival Advantage: Results From COMFORT-I

J. Dipersio, M. Arcasoy, H. Kantarjian, 2011 .

Current event‐free survival after sequential tyrosine kinase inhibitor therapy for chronic myeloid leukemia

H. Kantarjian, J. Cortes, A. Quintás-Cardama, 2011, Cancer.

Addition of navitoclax to ongoing ruxolitinib treatment in patients with myelofibrosis (REFINE): a post-hoc analysis of molecular biomarkers in a phase 2 study.

S. Verstovsek, Jacqueline S. Garcia, C. Harrison, 2022, The Lancet. Haematology.

The clinical dilemma of JAK inhibitor failure in myelofibrosis: Predictive characteristics and outcomes

S. Verstovsek, J. Mascarenhas, 2022, Cancer.

The Myelodepletive Phenotype in Myelofibrosis: Clinical Relevance and Therapeutic Implication.

S. Verstovsek, J. Mascarenhas, B. Marcellino, 2020, Clinical lymphoma, myeloma & leukemia.

MF management

S. Verstovsek, P. Bose, 2019, HemaSphere.

Significance of thrombocytopenia in patients with primary and postessential thrombocythemia/polycythemia vera myelofibrosis

H. Kantarjian, J. Cortes, S. Verstovsek, 2018, European journal of haematology.

JAK2V617F mutational frequency in polycythemia vera: 100%, >90%, less?

S. Verstovsek, A. Tefferi, R. Silver, 2006, Leukemia.

Clofarabine Plus Cytarabine (ARA-C) Combination Is Active in Newly Diagnosed Patients (PTS) ≥ Age 50 with Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS).

Z. Estrov, H. Kantarjian, G. Garcia-Manero, 2004 .

Long-term efficacy and safety of ruxolitinib versus best available therapy in polycythaemia vera (RESPONSE): 5-year follow up of a phase 3 study.

M. Griesshammer, S. Verstovsek, M. Hino, 2020, The Lancet. Haematology.

Outcome of patients with IDH1/2-mutated post-myeloproliferative neoplasm AML in the era of IDH inhibitors.

M. Konopleva, H. Kantarjian, S. Verstovsek, 2020, Blood advances.

Limitations of fibrosis grade as diagnostic criteria for post polycythemia vera and essential thrombocytosis myelofibrosis.

S. Verstovsek, A. Dueck, N. Daver, 2015, Leukemia research.

Diagnostic Performance of Erythropoietin Levels in Polycythemia Vera: Experience at a Comprehensive Cancer Center.

S. Verstovsek, Eric M Fountain, L. Masarová, 2020, Clinical lymphoma, myeloma & leukemia.

DNMT3A, TET2, and JAK2 mutations in polycythemia vera following long-term remission of secondary acute myeloid leukemia

Z. Estrov, S. Verstovsek, K. Patel, 2016, Leukemia & lymphoma.

Ruxolitinib versus best available therapy in patients with polycythemia vera: 80-week follow-up from the RESPONSE trial

M. Cazzola, M. Griesshammer, S. Verstovsek, 2016, Haematologica.

Analysis of 2013 European LeukaemiaNet (ELN) responses in chronic phase CML across four frontline TKI modalities and impact on clinical outcomes

H. Kantarjian, J. Cortes, S. Verstovsek, 2016, British journal of haematology.

Analysis of long term responses and their impact on outcomes in patients with chronic phase CML treated with four different TKI modalities – analysis of 5 prospective clinical trials

H. Kantarjian, J. Cortes, S. Verstovsek, 2016 .

Outcome after failure of second generation tyrosine kinase inhibitors treatment as first-line therapy for patients with chronic myeloid leukemia.

M. Konopleva, E. Burton, H. Kantarjian, 2013, Clinical lymphoma, myeloma & leukemia.

Cytogenetic and molecular responses and outcome in chronic myelogenous leukemia

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2008, Cancer.

A phase I , open-label , dose-escalation , multicenter study of the JAK 2 inhibitor NS-018 in patients with myelo fi brosis

S. Verstovsek, M. Wadleigh, M. Talpaz, 2016 .

Clinical validation of a multipurpose assay for detection and genotyping of CALR mutations in myeloproliferative neoplasms.

S. Verstovsek, R. Goswami, K. Patel, 2015, American journal of clinical pathology.

The Clinical Phenotype of Myelofibrosis Encompasses a Chronic Inflammatory State That Is Favorably Altered by INCB018424, a Selective Inhibitor of JAK1/2

H. Kantarjian, S. Verstovsek, R. Mesa, 2008 .

Experience with alemtuzumab plus rituximab in patients with relapsed and refractory lymphoid malignancies.

M. Andreeff, H. Kantarjian, G. Garcia-Manero, 2003, Blood.

Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial

J. Dipersio, M. Arcasoy, H. Kantarjian, 2017, Journal of Hematology & Oncology.

Ruxolitinib dose management as a key to long-term treatment success

S. Verstovsek, R. Mesa, R. Komrokji, 2016, International Journal of Hematology.

Insights from response to tyrosine kinase inhibitor therapy in a rare myeloproliferative neoplasm with CALR mutation and BCR-ABL1.

H. Kantarjian, J. Cortes, R. Luthra, 2015, Blood.

JAK inhibitors as therapy for myelofibrosis

S. Verstovsek, K. Newberry, 2015 .

Ruxolitinib and DNA methyltransferase-inhibitors: a foray into combination regimens in myelofibrosis

S. Verstovsek, N. Daver, 2015, Leukemia & lymphoma.

Treatment of the myeloid/lymphoid neoplasm with FGFR1 rearrangement with FGFR1 inhibitor.

S. Verstovsek, N. Daver, V. Subbiah, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Plasma vascular endothelial growth factor levels have prognostic significance in patients with acute myeloid leukemia but not in patients with myelodysplastic syndromes

E. Estey, H. Kantarjian, T. Manshouri, 2002, Cancer.

MK-0457, a Novel Aurora Kinase and BCR-ABL Inhibitor, Is Active Against BCR-ABL T315I Mutant Chronic Myelogenous Leukemia (CML).

D. Bergstrom, H. Kantarjian, J. Cortes, 2006 .

Effects of AMN107, a novel aminopyrimidine tyrosine kinase inhibitor, on human mast cells bearing wild-type or mutated codon 816 c-kit.

H. Kantarjian, J. Cortes, T. Manshouri, 2005, Leukemia research.

Patient Perceptions in Mast Cell Disorders.

S. Verstovsek, T. George, R. Zack, 2018, Immunology and allergy clinics of North America.

A Novel Unconventional Antigen MPD5 Elicits Anti-Tumor Humoral Immune Responses in a Subset of Patients with Polycythemia Vera

S. Verstovsek, R. Silver, J. Prchal, 2007, International journal of immunopathology and pharmacology.

Phase II study of troxacitabine, a novel dioxolane nucleoside analog, in patients with untreated or imatinib mesylate-resistant chronic myelogenous leukemia in blastic phase.

R. Larson, H. Kantarjian, J. Cortes, 2003, Leukemia research.

A Phase I Clinical Trial of Darinaparsin in Patients with Refractory Solid Tumors

C. Ng, R. Kurzrock, S. Verstovsek, 2009, Clinical Cancer Research.

Novel tumor antigens elicit anti-tumor humoral immune reactions in a subset of patients with polycythemia vera.

S. Verstovsek, R. Silver, J. Prchal, 2007, Clinical immunology.

Telomerase activity is prognostic in pediatric patients with acute myeloid leukemia

E. Estey, H. Kantarjian, J. Cortes, 2003, Cancer.

Lipopolysaccharide and splenic tumoricidal macrophage activation

M. J. Ehrke, S. Verstovsek, G. Zaleskis, 1994, Journal of leukocyte biology.

Clinical activity and safety of the histone deacetylase inhibitor MGCD0103: Results of a phase I study in patients with leukemia or myelodysplastic syndromes (MDS).

M. Minden, Z. Estrov, G. Garcia-Manero, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

myeloid leukemia (AML) in patients 50 years of age or older Clofarabine and cytarabine combination as induction therapy for acute

Z. Estrov, J. Cortes, S. Verstovsek, 2013 .

Superior outcome with hypomethylating therapy in patients with acute myeloid leukemia and high‐risk myelodysplastic syndrome and chromosome 5 and 7 abnormalities

J. Issa, H. Kantarjian, G. Garcia-Manero, 2009, Cancer.

Levels of soluble HLA-I and β2M in patients with acute myeloid leukemia and advanced myelodysplastic syndrome: association with clinical behavior and outcome of induction therapy

E. Estey, K. Do, H. Kantarjian, 2007, Leukemia.

Validation of the European Prognostic Index for younger adult patients with acute myeloid leukaemia in first relapse

H. Kantarjian, G. Garcia-Manero, S. Verstovsek, 2006, British journal of haematology.

Primary analysis of a phase II open-label trial of INCB039110, a selective JAK1 inhibitor, in patients with myelofibrosis

S. Verstovsek, R. Hoffman, R. Paquette, 2017, Haematologica.

At High Levels, Constitutively Activated STAT3 Induces Apoptosis of Chronic Lymphocytic Leukemia Cells

Z. Estrov, D. Harris, S. Verstovsek, 2016, The Journal of Immunology.

Phase I evaluation of XL019, an oral, potent, and selective JAK2 inhibitor.

H. Kantarjian, J. Cortes, S. Verstovsek, 2014, Leukemia research.

Phase I study of sorafenib in patients with refractory or relapsed acute leukemias

M. Konopleva, M. Andreeff, H. Kantarjian, 2011, Haematologica.

Outcome of patients with chronic myeloid leukemia with multiple ABL1 kinase domain mutations receiving tyrosine kinase inhibitor therapy

H. Kantarjian, J. Cortes, A. Quintás-Cardama, 2011, Haematologica.

TG101348, a JAK2-selective antagonist, inhibits primary hematopoietic cells derived from myeloproliferative disorder patients with JAK2V617F, MPLW515K or JAK2 exon 12 mutations as well as mutation negative patients

D. Gilliland, S. Verstovsek, A. Tefferi, 2008, Leukemia.

Immune modulation of minimal residual disease in early chronic phase chronic myelogenous leukemia

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2011, Cancer.

Sudden blastic transformation in patients with chronic myeloid leukemia treated with imatinib mesylate.

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2006, Blood.

Decitabine and Gemtuzumab Ozogamicin in Acute Myelogenous Leukemia and High-Risk Myelodysplastic Syndrome

M. Konopleva, Z. Estrov, H. Kantarjian, 2008 .

Lenalidomide therapy in myelofibrosis with myeloid metaplasia.

H. Kantarjian, S. Verstovsek, R. Mesa, 2006, Blood.

A Randomized Phase II Study of Low-Dose Decitabine Versus Azacitidine in Patients with Low- or Intermediate-1-Risk Myelodysplastic Syndromes: A Report on Behalf of the MDS Clinical Research Consortium

Z. Estrov, H. Kantarjian, G. Garcia-Manero, 2016 .

Low-Dose Hypomethylating Agents (HMAs) Are Effective in Patients (Pts) with Low- or Intermediate-1-Risk Myelodysplastic Syndrome (MDS): A Report on Behalf of the MDS Clinical Research Consortium

Z. Estrov, H. Kantarjian, G. Garcia-Manero, 2015 .

Primary autoimmune myelofibrosis in a 36-year-old patient presenting with isolated extreme anemia.

S. Verstovsek, S. Konoplev, Huifang Lu, 2010, Leukemia research.

Prognostic interaction between thrombocytosis and JAK2 V617F mutation in the WHO subcategories of myelodysplastic/myeloproliferative disease-unclassifiable and refractory anemia with ringed sideroblasts and marked thrombocytosis

H. Kantarjian, T. Manshouri, S. Verstovsek, 2008, Leukemia.

Ruxolitinib Re-Treatment in Patients with Myelofibrosis: Real-World Evidence on Patient Characteristics and Outcomes

S. Verstovsek, N. Pemmaraju, R. Scherber, 2022, Acta Haematologica.

Efficacy, safety and survival with ruxolitinib in patients with myelofibrosis: results of a median 2-year follow-up of COMFORT-I

J. Dipersio, M. Arcasoy, H. Kantarjian, 2013, Haematologica.

A phase 1‐2 study of a farnesyltransferase inhibitor, tipifarnib, combined with idarubicin and cytarabine for patients with newly diagnosed acute myeloid leukemia and high‐risk myelodysplastic syndrome

Z. Estrov, H. Kantarjian, G. Garcia-Manero, 2011, Cancer.

Hypomethylating Therapy in Patients with AML and High-Risk MDS and Chromosome 5 and 7 Abnormalities Is Associated with An Improved Outcome Compared to Conventional Chemotherapy

J. Issa, H. Kantarjian, G. Garcia-Manero, 2008 .

The effect of eltrombopag in managing thrombocytopenia associated with tyrosine kinase therapy in patients with chronic myeloid leukemia and myelofibrosis.

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2019, Journal of Clinical Oncology.

Long-Term Outcome of Ruxolitinib Treatment in Patients with Myelofibrosis: Durable Reductions in Spleen Volume, Improvements in Quality of Life, and Overall Survival Advantage in COMFORT-I

J. Dipersio, M. Arcasoy, H. Kantarjian, 2012 .

Ruxolitinib for the treatment of myelofibrosis.

S. Verstovsek, R. Vrhovac, A. Ostojic, 2011, Drugs of today.

A phase I/II study of INCB018424, an oral, selective JAK inhibitor, in patients with primary myelofibrosis (PMF) and post polycythemia vera/essential thrombocythemia myelofibrosis (Post-PV/ET MF)

H. Kantarjian, J. Cortes, S. Verstovsek, 2008 .

Decitabine Induces High Response Rates in Patients with Chronic Myelomonocytic Leukemia (CMML).

J. Issa, H. Kantarjian, G. Garcia-Manero, 2006 .

Activity of 9‐nitro‐camptothecin, an oral topoisomerase I inhibitor, in myelodysplastic syndrome and chronic myelomonocytic leukemia

H. Kantarjian, J. Cortes, A. Quintás-Cardama, 2006, Cancer.

Long‐term results of low‐intensity chemotherapy with clofarabine or cladribine combined with low‐dose cytarabine alternating with decitabine in older patients with newly diagnosed acute myeloid leukemia

M. Konopleva, Z. Estrov, H. Kantarjian, 2021, American journal of hematology.

Characteristics and outcomes of patients with multiple myeloma (MM) who develop therapy (t)-related myelodysplastic syndrome (MDS), t-chronic myelomonocytic leukemia (CMML), or t-acute myeloid leukemia (AML) patients underwent high-dose chemotherapy and autologous hematopoietic stem cell

J. Cortes, S. Verstovsek, F. Ravandi, 2015 .

Phase I Study Using Alternate Week Administration of the Farnesyl Transferase Inhibitor R115777 (Zarnestra™) in Patients with Myelodysplastic Syndrome.

E. Estey, R. Kurzrock, H. Kantarjian, 2004 .

Exploratory analysis of the effect of ruxolitinib on bone marrow morphology in patients with myelofibrosis.

H. Kantarjian, J. Cortes, S. Verstovsek, 2013 .

Clinical, genomic, and transcriptomic differences between myelodysplastic syndrome/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis (MDS/MPN‐RS‐T) and myelodysplastic syndrome with ring sideroblasts (MDS‐RS)

K. Do, H. Kantarjian, G. Garcia-Manero, 2021, American journal of hematology.

Results from Ongoing Phase 1/2 Clinical Trial of Tagraxofusp (SL-401) in Patients with Relapsed/Refractory Chronic Myelomonocytic Leukemia (CMML)

S. Verstovsek, C. Brooks, M. Talpaz, 2018, Blood.

Myelodysplastic Syndrome with Fibrosis: Experience of a Single-Institution with 139 Patients.

H. Kantarjian, G. Garcia-Manero, S. Verstovsek, 2009 .

Clinical and Molecular Response in Core Binding Factor Acute Myelogenous Leukemia with Fludarabine, Cytarabine, G-CSF and Gemtuzumab Ozogamicin.

Z. Estrov, H. Kantarjian, S. Verstovsek, 2008 .

Characteristics and outcome of patients with acute myeloid leukemia refractory to 1 cycle of high-dose cytarabine-based induction chemotherapy.

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2009, Blood.

Phase I Study of Clofarabine Plus Idarubicin and Clofarabine Plus Idarubicin Plus Cytarabine (ARA-C) in Patients (PTS) with Relapsed and Primary Refractory Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), and Myeloid Blast Phase of Chronic Myeloid Leukemia (CML).

E. Estey, H. Kantarjian, G. Garcia-Manero, 2004 .

A Phase I and Pharmacokinetic Study of VNP40101M, a Novel Sulfonylhydrazine Alkylating Agent, in Patients with Refractory Leukemia

M. Andreeff, M. Sznol, H. Kantarjian, 2004, Clinical Cancer Research.

Clinical value of event-free survival in acute myeloid leukemia.

M. Konopleva, M. Andreeff, H. Kantarjian, 2020, Blood advances.

Quality of life independently predicts overall survival in myelofibrosis: Key insights from the COntrolled MyeloFibrosis Study with ORal Janus kinase inhibitor Treatment (COMFORT)‐I study

Angela G. Fleischman, S. Verstovsek, A. Dueck, 2022, British journal of haematology.

Perspective: Pivotal translational hematology and therapeutic insights in chronic myeloid hematopoietic stem cell malignancies

R. Bejar, T. Brümmendorf, T. Barbui, 2022, Hematological oncology.

The role of thrombocytapheresis in the contemporary management of hyperthrombocytosis in myeloproliferative neoplasms: A case-based review.

S. Verstovsek, C. Hosing, K. Newberry, 2017, Leukemia research.

Single-center experience with venetoclax combinations in patients with newly diagnosed and relapsed AML evolving from MPNs.

M. Konopleva, Z. Estrov, S. Verstovsek, 2021, Blood advances.

Prognostic value of measurable residual disease after venetoclax and decitabine in acute myeloid leukemia.

M. Konopleva, M. Andreeff, H. Kantarjian, 2020, Blood advances.

Advances in Risk Stratification and Treatment of Polycythemia Vera and Essential Thrombocythemia

S. Verstovsek, M. Lucijanić, I. Krečak, 2022, Current Hematologic Malignancy Reports.

Use of pegylated interferon in young patients with polycythemia vera and essential thrombocythemia

L. Resar, S. Verstovsek, R. Hoffman, 2020, Pediatric blood & cancer.

Efficacy and safety of ruxolitinib after and versus interferon use in the RESPONSE studies

M. Griesshammer, S. Verstovsek, P. Guglielmelli, 2018, Annals of Hematology.

Histomorphological responses after therapy with pegylated interferon α-2a in patients with essential thrombocythemia (ET) and polycythemia vera (PV)

M. Konopleva, H. Kantarjian, J. Cortes, 2017, Experimental Hematology & Oncology.

Ruxolitinib reduces JAK2 p.V617F allele burden in patients with polycythemia vera enrolled in the RESPONSE study

M. Griesshammer, S. Verstovsek, P. Guglielmelli, 2017, Annals of Hematology.

Pegylated interferon alfa-2a in patients with essential thrombocythaemia or polycythaemia vera: a post-hoc, median 83 month follow-up of an open-label, phase 2 trial.

M. Konopleva, Z. Estrov, H. Kantarjian, 2017, The Lancet. Haematology.

New therapeutic approaches in PV

S. Verstovsek, K. Newberry, L. Falchi, 2015 .

Therapeutic options for patients with polycythemia vera and essential thrombocythemia refractory/resistant to hydroxyurea

M. Sever, S. Verstovsek, K. Newberry, 2014, Leukemia & lymphoma.

Pegylated Interferon-alfa-2a (PEG-IFN-α-2A; PEGASYS™) for Essential Thrombocythemia (ET) and Polycythemia Vera (PV): An Update of an Ongoing Phase II Study.

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2007 .

PEG‐IFN‐α‐2b therapy in BCR‐ABL–negative myeloproliferative disorders

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2007 .

PEG-IFN-alpha-2b therapy in BCR-ABL-negative myeloproliferative disorders: final result of a phase 2 study.

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2007, Cancer.

Pilot study of pegylated interferon-alpha 2b in patients with essential thrombocythemia

Z. Estrov, H. Kantarjian, J. Cortes, 2002, Cancer Chemotherapy and Pharmacology.

A Phase 2 Study of Luspatercept in Patients with Myelofibrosis-Associated Anemia

A. Mead, S. Verstovsek, T. Gerike, 2019, Blood.

Phase I Study of Cloretazine (VNP40101M), a Novel Sulfonylhydrazine Alkylating Agent, Combined with Cytarabine in Patients with Refractory Leukemia

M. Sznol, H. Kantarjian, G. Garcia-Manero, 2005, Clinical Cancer Research.

Significance of deeper molecular responses in patients with chronic myeloid leukemia in early chronic phase treated with tyrosine kinase inhibitors

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2013, American journal of hematology.

Early responses predict better outcomes in patients with newly diagnosed chronic myeloid leukemia: results with four tyrosine kinase inhibitor modalities.

H. Kantarjian, J. Cortes, A. Quintás-Cardama, 2013, Blood.

The clinical significance of achieving different levels of cytogenetic response in patients with chronic phase chronic myeloid leukemia after failure to front-line therapy: is complete cytogenetic response the only desirable endpoint?

E. Burton, H. Kantarjian, G. Garcia-Manero, 2011, Clinical lymphoma, myeloma & leukemia.

Outcome with the Hyper-CVAD and Imatinib Mesylate Regimen as Frontline Therapy for Adult Philadelphia (Ph) Positive Acute Lymphocytic Leukemia (ALL).

M. Andreeff, H. Kantarjian, G. Garcia-Manero, 2006 .

Update of the Hyper-CVAD and Imatinib Mesylate Regimen in Philadelphia (Ph) Positive Acute Lymphocytic Leukemia (ALL).

M. Andreeff, H. Kantarjian, J. Cortes, 2004 .

Molecular Responses in Patients with Chronic Myelogenous Leukemia in Chronic Phase Treated with Imatinib Mesylate

Susan O'Brien, Jorge Cortes, Rajyalakshmi Luthra, 2005, Clinical Cancer Research.

Outcomes of patients with chronic phase chronic myeloid leukemia (CML-CP) after discontinuation of frontline ponatinib therapy

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2019, Leukemia & lymphoma.

Chronic myeloid leukemia (CML) with P190 BCR-ABL: analysis of characteristics, outcomes, and prognostic significance.

H. Kantarjian, S. Verstovsek, G. Borthakur, 2009, Blood.

Is there still a role for interferon-alpha for newly diagnosed chronic myeloid leukemia in chronic phase?

A. Quintás-Cardama, S. Verstovsek, 2007, Leukemia & lymphoma.

Cladribine and low-dose cytarabine alternating with decitabine as front-line therapy for elderly patients with acute myeloid leukaemia: a phase 2 single-arm trial.

Susan O'Brien, Koji Sasaki, Naveen Pemmaraju, 2018, The Lancet. Haematology.

Long‐term results of a phase 2 trial of nilotinib 400 mg twice daily in newly diagnosed patients with chronic‐phase chronic myeloid leukemia

M. Konopleva, Z. Estrov, H. Kantarjian, 2020, Cancer.

chronic myeloid leukemia in accelerated or blast phase inhibitors is associated with a poor prognosis among patients with major cytogenetic response with second-generation tyrosine kinase Failure to achieve a complete hematologic response at the time of a

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2013 .

Failure to achieve a complete hematologic response at the time of a major cytogenetic response with second-generation tyrosine kinase inhibitors is associated with a poor prognosis among patients with chronic myeloid leukemia in accelerated or blast phase.

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2009, Blood.

Phase I Study of Lonafarnib (SCH66336) in Combination with Imatinib for Patients (Pts) with Chronic Myeloid Leukemia (CML) after Failure to Imatinib.

G. Daley, H. Kantarjian, J. Cortes, 2004 .

Decitabine Induces Responses in Patients with Myelodysplastic Syndrome (MDS) after Failure of Azacitidine Therapy.

J. Issa, H. Kantarjian, G. Garcia-Manero, 2006 .

Primary myelofibrosis (PMF), post polycythemia vera myelofibrosis (post-PV MF), post essential thrombocythemia myelofibrosis (post-ET MF), blast phase PMF (PMF-BP): Consensus on terminology by the international working group for myelofibrosis research and treatment (IWG-MRT).

Francisco Cervantes, Giovanni Barosi, Juergen Thiele, 2007, Leukemia research.

Management of cytopenias in patients with myelofibrosis treated with ruxolitinib and effect of dose modifications on efficacy outcomes

H. Kantarjian, A. Quintás-Cardama, S. Verstovsek, 2013, OncoTargets and therapy.

Prognostic implications and clinical characteristics associated with bone marrow fibrosis in patients with myelofibrosis

Z. Estrov, H. Kantarjian, J. Cortes, 2011, Leukemia & lymphoma.

MPN-associated myelofibrosis (MPN-MF).

A. Green, S. Verstovsek, R. Gale, 2011, Leukemia research.

Phase II study of sunitinib in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis.

H. Kantarjian, S. Verstovsek, G. Borthakur, 2010, Clinical lymphoma, myeloma & leukemia.

Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate.

Steven M Kornblau, Susan O'Brien, Jorge Cortes, 2004, Blood.

Prognostic impact of deletions of derivative chromosome 9 in patients with chronic myelogenous leukemia treated with nilotinib or dasatinib

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2011, Cancer.

Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis.

Ayalew Tefferi, Z. Estrov, H. Kantarjian, 2010, The New England journal of medicine.

Defining disease modification in myelofibrosis in the era of targeted therapy

K. Döhner, A. Mead, S. Verstovsek, 2022, Cancer.

Efficacy and safety of ruxolitinib in patients with myelofibrosis and low platelet count (50 × 109/L to <100 × 109/L) at baseline: the final analysis of EXPAND

S. Verstovsek, D. Niederwieser, P. Guglielmelli, 2022, Therapeutic advances in hematology.

Pentraxin‐3 plasma levels correlate with tumour burden and overall survival in patients with primary myelofibrosis

Z. Estrov, T. Manshouri, S. Verstovsek, 2018, British journal of haematology.

Ruxolitinib for symptom control in patients with Chronic Lymphocytic leukemia: A Phase II Trial

C. Cleeland, Z. Estrov, D. Harris, 2017, The Lancet. Haematology.

Complete remission in a patient with JAK2- and IDH2-positive myelofibrosis.

H. Kantarjian, S. Verstovsek, Wei Wang, 2016, Blood.

Phase II study of pomalidomide in combination with prednisone in patients with myelofibrosis and significant anemia.

H. Kantarjian, J. Cortes, S. Verstovsek, 2014, Leukemia research.

Changing myelofibrosis's natural course at last.

S. Verstovsek, 2014, Blood.

Breakthroughs in myeloproliferative neoplasms

S. Verstovsek, F. P. Santos, 2012, Hematology.

The Myelofibrosis Symptom Assessment Form (MFSAF): an evidence-based brief inventory to measure quality of life and symptomatic response to treatment in myelofibrosis.

J. Sloan, H. Kantarjian, S. Verstovsek, 2009, Leukemia research.

Prognostic significance of additional chromosomal abnormalities at the time of diagnosis in patients with chronic myeloid leukemia treated with frontline tyrosine kinase inhibitors

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2018, American journal of hematology.

Therapeutic Approach to Young Patients With Low-Risk Essential Thrombocythemia: Primum Non Nocere.

S. Verstovsek, L. Masarová, 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Approach to patients with essential thrombocythaemia and very high platelet counts: what is the evidence for treatment?

S. Verstovsek, K. Newberry, L. Falchi, 2017, British journal of haematology.

Phase II study of single-agent nivolumab in patients with myelofibrosis

G. Garcia-Manero, S. Verstovsek, N. Daver, 2021, Annals of Hematology.

Outcome in patients with nonleukemic granulocytic sarcoma treated with chemotherapy with or without radiotherapy

E. Estey, H. Kantarjian, G. Garcia-Manero, 2003, Leukemia.

Mylotarg, fludarabine, cytarabine (ara-C), and cyclosporine (MFAC) regimen as post-remission therapy in acute myelogenous leukemia

E. Estey, H. Kantarjian, G. Garcia-Manero, 2003, Cancer Chemotherapy and Pharmacology.

SURPASS-ET: phase III study of ropeginterferon alfa-2b versus anagrelide as second-line therapy in essential thrombocythemia.

S. Verstovsek, R. Mesa, W. Shih, 2022, Future oncology.

Treatment with Pegylated Interferon-Alfa-2A (PEG-IFN-α-2A; PEGASYS™) for Patients with Essential Thrombocythemia (ET) and Polycythemia Vera (PV).

H. Kantarjian, J. Cortes, A. Quintás-Cardama, 2006 .

Pegylated interferon therapy for patients with Philadelphia chromosome-negative myeloproliferative disorders.

H. Kantarjian, A. Quintás-Cardama, S. Verstovsek, 2006, Seminars in thrombosis and hemostasis.

Ten-day Decitabine with Venetoclax in Acute Myeloid Leukemia: A Single-arm Phase 2 Trial

Z. Estrov, S. Verstovsek, Koichi Takahashi, 2020 .

Phase II study of alemtuzumab in combination with pentostatin in patients with T-cell neoplasms.

H. Kantarjian, S. Verstovsek, Xuelin Huang, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Cytogenetic abnormalities in essential thrombocythemia at presentation and transformation

Z. Estrov, H. Kantarjian, J. Cortes, 2009, International journal of hematology.

A phase 1/2, open-label study evaluating twice-daily administration of momelotinib in myelofibrosis

S. Verstovsek, M. Deininger, R. Mesa, 2017, Haematologica.

Pomalidomide is active in the treatment of anemia associated with myelofibrosis.

H. Deeg, H. Kantarjian, S. Verstovsek, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

5-Azacitidine has limited therapeutic activity in myelofibrosis

S. Verstovsek, R. Mesa, A. Tefferi, 2009, Leukemia.

Phase II Study of Lenalidomide (CC-5013, Revlimid®) for Patients (pts) with Myelofibrosis (MF).

H. Kantarjian, J. Cortes, S. Verstovsek, 2005 .

Dasatinib-responsive mast cell neoplasms as initial presentation of chronic myelogenous leukemia in blast phase.

B. Esmaeli, J. Cortes, S. Verstovsek, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Sustained Complete Molecular Response to Imatinib in Chronic Myeloid Leukemia (CML): a Target Worth Aiming and Achieving?.

A. Verma, H. Kantarjian, J. Cortes, 2009 .

Distinct patterns of cytogenetic and clinical progression in chronic myeloproliferative neoplasms with or without JAK2 or MPL mutations.

S. Verstovsek, B. Barkoh, P. Lennon, 2010, Cancer genetics and cytogenetics.

Z. Estrov, H. Kantarjian, J. Cortes, 2017, Blood advances.

Primary myelofibrosis with concurrent precursor T-cell lymphoblastic lymphoma of the spleen in a 26-year-old patient.

M. Sever, S. Verstovsek, J. Jorgensen, 2009, Leukemia research.

Running title: Sorafenib in hematologic malignancies

M. Konopleva, M. Andreeff, H. Kantarjian, 2010 .

Clofarabine and Clofarabine Plus Low-Dose Cytarabine (ara-C) as Induction Therapy for Patients (pts) ≥ 60 Years with Newly Diagnosed Acute Myeloid Leukemia (AML).

Z. Estrov, H. Kantarjian, G. Garcia-Manero, 2005 .

TP53 mutation is rare in primary myelofibrosis

S. Verstovsek, K. Patel, C. Bueso-Ramos, 2011, Leukemia & lymphoma.

Flow cytometric immunophenotypic analysis of systemic mastocytosis involving bone marrow.

S. Verstovsek, L. Medeiros, J. Jorgensen, 2014, Archives of pathology & laboratory medicine.

Avapritinib for Systemic Mastocytosis

S. Verstovsek, P. Bose, 2021, Expert Review of Hematology.

Mast cell leukemia (MCL): Clinico-pathologic and molecular features and survival outcome.

H. Kantarjian, J. Cortes, S. Verstovsek, 2017, Leukemia research.

Clofarabine combinations as acute myeloid leukemia salvage therapy

Z. Estrov, H. Kantarjian, S. Verstovsek, 2008, Cancer.

Spinal epidural granulocytic sarcoma in non-leukemic patient

D. Grujičić, S. Verstovsek, I. Elezović, 2009, International journal of hematology.

Granulocytic sarcoma with massive scalp involvement

A. Quintás-Cardama, S. Verstovsek, H. Amin, 2008, American journal of hematology.

Myeloid neoplasms with 8q24/MYC rearrangement are frequently associated with myelodysplasia, complex karyotype, TP53 alterations, and inferior survival

G. Garcia-Manero, S. Verstovsek, C. Dinardo, 2022, British journal of haematology.

Management of patients with systemic mastocytosis: Review of M. D. Anderson Cancer Center experience

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2004, American journal of hematology.

Refined diagnostic criteria and classification of mast cell leukemia (MCL) and myelomastocytic leukemia (MML): a consensus proposal.

M. Triggiani, A. Órfão, H. Kluin-Nelemans, 2014 .

PACIFICA: A Randomized, Controlled Phase 3 Study of Pacritinib Versus Physician's Choice in Patients with Primary or Secondary Myelofibrosis and Severe Thrombocytopenia

K. Döhner, S. Verstovsek, C. Harrison, 2021, Blood.

MPN-343: The BET Inhibitor Pelabresib Decreases Inflammatory Cytokines, Improves Bone Marrow Fibrosis and Function, and Demonstrates Clinical Response Irrespective of Mutation Status in Myelofibrosis Patients in the Phase 2 MANIFEST Trial

P. Trojer, M. Salama, S. Verstovsek, 2021 .

The Addition of Navitoclax to Ruxolitinib Demonstrates Efficacy within Different High-Risk Populations in Patients with Relapsed/Refractory Myelofibrosis

S. Verstovsek, Jacqueline S. Garcia, C. Harrison, 2020 .

Robust Overall Survival and Sustained Efficacy Outcomes during Long Term Exposure to Momelotinib in JAK Inhibitor Naïve and Previously JAK Inhibitor Treated Intermediate/High Risk Myelofibrosis Patients

S. Verstovsek, R. Mesa, F. Passamonti, 2020 .

MPN-377: Updated Results from a Phase 1/2 Clinical Trial of Tagraxofusp, a CD123-Targeted Therapy, in Patients with Poor-Risk Myelofibrosis

S. Verstovsek, C. Brooks, M. Talpaz, 2020 .

Competing cell clones in myeloproliferative neoplasm.

H. Kantarjian, J. Cortes, S. Verstovsek, 2010, Blood.

Transient down-modulation of CD20 by rituximab in patients with chronic lymphocytic leukemia.

H. Kantarjian, S. Verstovsek, M. Keating, 2003, Blood.

How We Treat Patients With Polycythemia Vera

S. Verstovsek, P. Bose, 2017 .

Phase I Study of the Oral Histone Deacetylase Inhibitor SB939 In Patients with Advanced Hematologic Malignancies

G. Wilding, H. Kantarjian, G. Garcia-Manero, 2010 .

A Phase I Study of the Combination of the Histone Deacetylase Inhibitor Vorinostat with Idarubicin in Advanced Acute Leukemia.

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2007 .

Use of Expanded Allogeneic Third Party BK Virus Specific Cytotoxic T Cells to Target Progressive Multifocal Leukoencephalopathy

K. Rezvani, D. Marin, E. Shpall, 2016 .

Imatinib therapy in a patient with suspected chronic neutrophilic leukemia and FIP1L1-PDGFRA rearrangement.

H. Kantarjian, S. Verstovsek, J. Khoury, 2013, Blood.

Imatinib has limited therapeutic activity for hypereosinophilic syndrome patients with unknown or negative PDGFRalpha mutation status.

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2009, Leukemia research.

New Haematological Indications for Imatinib

S. Verstovsek, 2007 .

The novel tyrosine kinase inhibitor EXEL-0862 induces apoptosis in human FIP1L1-PDGFR-α-expressing cells through caspase-3-mediated cleavage of Mcl-1

H. Kantarjian, J. Cortes, T. Manshouri, 2007, Leukemia.

Activity of AMN107, a novel aminopyrimidine tyrosine kinase inhibitor, against human FIP1L1-PDGFR-alpha-expressing cells.

H. Kantarjian, J. Cortes, T. Manshouri, 2006, Leukemia research.

2‐Chlorodeoxyadenosine and cytarabine combination therapy for idiopathic hypereosinophilic syndrome

M. Andreeff, H. Kantarjian, G. Garcia-Manero, 2005, Cancer.

Mutations and promoter methylation status of NPM1 in myeloproliferative disorders.

J. Issa, J. Jelinek, Y. Oki, 2006, Haematologica.

Cases in the management of polycythemia vera: switching from hydroxyurea to ruxolitinib to resolve symptoms and improve quality of life.

S. Verstovsek, 2022, Clinical advances in hematology & oncology : H&O.

Changes in the incidence and overall survival of patients with myeloproliferative neoplasms between 2002 and 2016 in the United States

S. Verstovsek, R. Scherber, S. Verma, 2020, Leukemia & lymphoma.

Comprehensive haematological control with ruxolitinib in patients with polycythaemia vera resistant to or intolerant of hydroxycarbamide

M. Griesshammer, S. Verstovsek, P. Guglielmelli, 2018, British journal of haematology.

The efficacy and safety of continued hydroxycarbamide therapy versus switching to ruxolitinib in patients with polycythaemia vera: a randomized, double‐blind, double‐dummy, symptom study (RELIEF)

J. Byrne, S. Verstovsek, R. Mesa, 2014, British journal of haematology.

Highlights in polycythemia vera from the 2016 EHA congress.

S. Verstovsek, 2016, Clinical advances in hematology & oncology : H&O.

Baseline Characteristics and Symptom Burden in RESPONSE: A Randomized, Open-Label, Phase 3 Study of Ruxolitinib In Polycythemia Vera Patients Resistant to or Intolerant of Hydroxyurea

M. Griesshammer, S. Verstovsek, C. Harrison, 2013 .

Phase I and pharmacodynamic study of Triapine, a novel ribonucleotide reductase inhibitor, in patients with advanced leukemia.

J. Dipersio, M. Sznol, H. Kantarjian, 2003, Leukemia research.

How early intervention impacts long-term survival in myelofibrosis.

S. Verstovsek, 2022, Clinical advances in hematology & oncology : H&O.

Safety and efficacy of fedratinib, a selective oral inhibitor of Janus kinase‐2 (JAK2), in patients with myelofibrosis and low pretreatment platelet counts

S. Verstovsek, R. Mesa, M. Talpaz, 2022, British journal of haematology.

Managing patients with myelofibrosis and thrombocytopenia

S. Verstovsek, M. Yilmaz, 2022, Expert review of hematology.

Real-world survival of US patients with intermediate- to high-risk myelofibrosis: impact of ruxolitinib approval

S. Verstovsek, C. Harrison, S. Parasuraman, 2021, Annals of Hematology.

Retrospective analysis of pacritinib in patients with myelofibrosis and severe thrombocytopenia

S. Verstovsek, R. Mesa, M. Talpaz, 2021, Haematologica.

A phase Ib study to assess the efficacy and safety of vismodegib in combination with ruxolitinib in patients with intermediate- or high-risk myelofibrosis

S. Verstovsek, F. Passamonti, S. Koschmieder, 2018, Journal of Hematology & Oncology.

Clinical use of ruxolitinib in an academic medical center in unselected patients with myeloproliferative neoplasms not on clinical study

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2017, Leukemia & lymphoma.

The impact of anemia on overall survival in patients with myelofibrosis treated with ruxolitinib in the COMFORT studies

H. Kantarjian, S. Verstovsek, C. Harrison, 2016, Haematologica.

Therapeutic benefit of decitabine, a hypomethylating agent, in patients with high-risk primary myelofibrosis and myeloproliferative neoplasm in accelerated or blastic/acute myeloid leukemia phase.

H. Kantarjian, J. Cortes, S. Verstovsek, 2015, Leukemia research.

A Phase 2 Study of INCB018424, An Oral, Selective JAK1/JAK2 Inhibitor, in Patients with Advanced Polycythemia Vera (PV) and Essential Thrombocythemia (ET) Refractory to Hydroxyurea.

M. Cazzola, T. Barbui, H. Kantarjian, 2009 .

Advances in Brief Mutation in the ATP-binding Pocket of the ABL Kinase Domain in an STI 571-resistant BCR / ABL-positive Cell Line 1

H. Kantarjian, S. Verstovsek, V. Divoky, 2002 .

Lymphocytic variant of hypereosinophilic syndrome: A report of seven cases from a single institution

Z. Estrov, S. Verstovsek, L. Medeiros, 2020, Cytometry. Part B, Clinical cytometry.

mutation-dependent and -independent imatinib resistance Adaphostin-induced oxidative stress overcomes BCR/ABL

E. Sausville, Z. Estrov, K. Bhalla, 2013 .

Adaphostin-induced oxidative stress overcomes BCR/ABL mutation-dependent and -independent imatinib resistance.

E. Sausville, Z. Estrov, K. Bhalla, 2006, Blood.

Phase II study of the hyper-CVAD regimen in combination with ofatumumab as frontline therapy for adults with CD-20 positive ALL.

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2014 .

Utility of the World Heath Organization classification criteria for the diagnosis of systemic mastocytosis in bone marrow

T. Manshouri, R. Luthra, S. Verstovsek, 2009, Modern Pathology.

Pacritinib vs Best Available Therapy, Including Ruxolitinib, in Patients With Myelofibrosis: A Randomized Clinical Trial

S. Verstovsek, R. Hoffman, R. Mesa, 2018, JAMA oncology.

Results for Phase II Clinical Trial of LCL161, a SMAC Mimetic, in Patients with Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (post-PV MF) or Post-Essential Thrombocytosis Myelofibrosis (post-ET MF)

Z. Estrov, H. Kantarjian, G. Garcia-Manero, 2016 .

Phase I/II Study of the Mammalian Target of Rapamycin Inhibitor Everolimus (RAD001) in Patients with Relapsed or Refractory Hematologic Malignancies

M. Konopleva, M. Andreeff, S. Verstovsek, 2006, Clinical Cancer Research.

A Phase II Study of Temsirolimus (CCI-779) in Patients with Advanced Leukemias.

J. Dancey, M. Andreeff, G. Garcia-Manero, 2004 .

Pregnancy in a patient with hypereosinophilic syndrome.

J. Cortes, S. Verstovsek, M. Keating, 2009, Leukemia research.

The underappreciated risk of thrombosis and bleeding in patients with myelofibrosis: a review

S. Verstovsek, L. Falchi, Devendra Kc, 2017, Annals of Hematology.

SOHO State of the Art Updates and Next Questions: Identifying and Treating "Progression" in Myelofibrosis.

S. Verstovsek, P. Bose, 2021, Clinical lymphoma, myeloma & leukemia.

Heterodimeric JAK-STAT Activation as a Mechanism of Persistence to JAK2 Inhibitor Therapy

B. Bernstein, B. Ebert, Mazhar Adli, 2011, Nature.

A Phase I Study of the Histone Deacetylase Inhibitor MGCD0103 (MG-0103) Given as a Three-Times Weekly Oral Dose in Patients with Leukemia or Myelodysplastic Syndromes (MDS).

M. Minden, Z. Estrov, H. Kantarjian, 2005 .

A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis.

Jason Gotlib, Moshe Talpaz, J. Dipersio, 2012, The New England journal of medicine.

Validation of the Serial Use of the Myelofibrosis Symptom Assessment Form (MF-SAF) for Measuring Symptomatic Improvement: Performance in 86 Myelofibrosis Patients On INCB018424 Clinical Trial.

Z. Estrov, H. Kantarjian, S. Verstovsek, 2009 .

Impact of SF3B1 mutation in myelofibrosis

H. Kantarjian, G. Garcia-Manero, S. Verstovsek, 2022, Leukemia & lymphoma.

Discovery and Preclinical Characterization of INCB018424, a Selective JAK2 Inhibitor for the Treatment of Myeloproliferative Disorders.

S. Verstovsek, J. Fridman, P. Scherle, 2007 .

New Therapies in Development for Myelofibrosis.

S. Verstovsek, H. Chifotides, 2020, Clinical lymphoma, myeloma & leukemia.

Results of a phase I/II study of the combination of 5-aza-2’-deoxycytidine and valproic acid in patients with acute myeloid leukemia and myelodysplastic syndrome

G. Rosner, Hushan Yang, J. Issa, 2005 .

Clofarabine Plus Anthracycline Combinations in Acute Myeloid Leukemia (AML) Salvage.

Z. Estrov, M. Andreeff, H. Kantarjian, 2006 .

Protective specific immunity induced by doxorubicin plus TNF‐α combination treatment of EL4 lymphoma–bearing C57BL/6 mice

M. J. Ehrke, S. Verstovsek, G. Zaleskis, 2000, International journal of cancer.

Hemizygous/Homozygous and Heterozygous JAK2 Mutation Detected in Plasma of Patients with Myeloproliferative Diseases: Correlation with Clinical Behavior.

H. Kantarjian, J. Cortes, S. Verstovsek, 2005 .

Interim Results from Fight-203, a Phase 2, Open-Label, Multicenter Study Evaluating the Efficacy and Safety of Pemigatinib (INCB054828) in Patients with Myeloid/Lymphoid Neoplasms with Rearrangement of Fibroblast Growth Factor Receptor 1 (FGFR1)

A. Mead, S. Verstovsek, A. Vannucchi, 2018, Blood.

Myeloid/lymphoid neoplasms with FGFR1 rearrangement

V. Najfeld, H. Kantarjian, G. Garcia-Manero, 2018, Leukemia & lymphoma.

Histomorphological Responses after Therapy with Pegylated Interferon Alpha-2a in Patients with Essential Thrombocythemia (ET) and Polycythemia Vera (PV)

M. Konopleva, H. Kantarjian, J. Cortes, 2016 .

Intravenous Voriconazole (IV-VORI) Prevents Invasive Fungal Infections (IFI) in Patients (pts) with Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS).

E. Estey, H. Kantarjian, S. Verstovsek, 2004 .

Update of the Modified Hyper-CVAD Regimen with or without Rituximab in Newly Diagnosed Adult Acute Lymphocytic Leukemia (ALL).

M. Andreeff, H. Kantarjian, G. Garcia-Manero, 2005 .

Cyclophosphamide plus tumor necrosis factor‐α chemoimmunotherapy cured mice: Life‐long immunity and rejection of re‐implanted primary lymphoma

M. J. Ehrke, S. Verstovsek, G. Zaleskis, 1995, International journal of cancer.

Arsenic derivatives as therapeutic agents for hematologic malignancies.

Z. Estrov, S. Verstovsek, 2004, Leukemia research.

Durable remission with rituximab in a patient with an unusual variant of Castleman's disease with myelofibrosis—TAFRO syndrome

Z. Estrov, S. Verstovsek, K. Patel, 2015, American journal of hematology.

Chronic idiopathic myelofibrosis

J. Cortes, S. Verstovsek, 2008 .

Biological drivers of clinical phenotype in myelofibrosis

W. Vainchenker, R. Schneider, S. Verstovsek, 2022, Leukemia.

Patients with post-essential thrombocythemia and post-polycythemia vera differ from patients with primary myelofibrosis.

H. Kantarjian, J. Cortes, T. Manshouri, 2015, Leukemia research.

Nuclear factor‐KappaB modulation as a therapeutic approach in hematologic malignancies

S. Verstovsek, F. Giles, A. Panwalkar, 2004, Cancer.

Final Update of Phase I-II Study of the Farnesyltransferase Inhibitor Tipifarnib in Combination with Idarubicin and Cytarabine for Patients with Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome.

Z. Estrov, H. Kantarjian, G. Garcia-Manero, 2007 .

Intensively Timed Induction (ITI) Chemotherapy in Adults with Acute Myelogenous Leukemia (AML).

E. Estey, G. Garcia-Manero, S. Verstovsek, 2007 .

Prognostic significance of cellular vascular endothelial growth factor expression in chronic phase chronic myeloid leukemia.

H. Kantarjian, J. Cortes, T. Manshouri, 2002, Blood.

Primary autoimmune myelofibrosis: a case report and review of the literature

S. Verstovsek, C. Bueso-Ramos, Sa A. Wang, 2017, International Journal of Hematology.

Primary autoimmune myelofibrosis (MF) with high‐grade peripheral T‐cell lymphoma (PTCL) NOS

S. Verstovsek, P. Jain, C. Bueso-Ramos, 2013, European journal of haematology.

Clofarabine and cytarabine combination as induction therapy for acute myeloid leukemia (AML) in patients 50 years of age or older.

Z. Estrov, H. Kantarjian, G. Garcia-Manero, 2006, Blood.

The evolution of arsenic in the treatment of acute promyelocytic leukemia and other myeloid neoplasms: Moving toward an effective oral, outpatient therapy

H. Kantarjian, S. Verstovsek, L. Falchi, 2016, Cancer.

Chemical and clinical development of darinaparsin, a novel organic arsenic derivative.

H. Kantarjian, A. Quintás-Cardama, S. Verstovsek, 2008, Anti-cancer agents in medicinal chemistry.

Development of an organic arsenic derivative as a therapy for leukaemia

H. Kantarjian, J. Cortes, S. Verstovsek, 2003 .

In vitro activity of dimethylarsinic acid against human leukemia and multiple myeloma cell lines

H. Kantarjian, S. Verstovsek, E. Freireich, 2003, Cancer Chemotherapy and Pharmacology.

Phase I study of S-trans, trans-farnesylthiosalicylic acid (salirasib), a novel oral RAS inhibitor in patients with refractory hematologic malignancies.

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2015, Clinical lymphoma, myeloma & leukemia.

Open-Label, Randomized Comparison of Itraconazole versus Caspofungin for Prophylaxis in Patients with Hematologic Malignancies

E. Estey, S. Verstovsek, S. O'brien, 2006, Antimicrobial Agents and Chemotherapy.

Splenomegaly in patients with primary or secondary myelofibrosis who are candidates for allogeneic hematopoietic cell transplantation: a Position Paper on behalf of the Chronic Malignancies Working Party of the EBMT.

T. Barbui, M. Robin, I. Yakoub-Agha, 2022, The Lancet. Haematology.

Treating Leukemia in the Time of COVID-19

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2020, Acta Haematologica.

CD26 in T-cell lymphomas: a potential clinical role?

S. Verstovsek, F. Cabanillas, N. Dang, 2000, Oncology.

Analysis of cardiovascular and arteriothrombotic adverse events in chronic-phase CML patients after frontline TKIs.

Z. Estrov, H. Kantarjian, G. Garcia-Manero, 2019, Blood advances.

The anti-angiogenesis agent, AG-013736, has minimal activity in elderly patients with poor prognosis acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS).

Z. Estrov, S. Verstovsek, P. Bycott, 2006, Leukemia research.

Results of a Phase I/II Study of the Combination of 5-aza-2′-Deoxycytidine (DAC) and Valproic Acid (VPA) in Patients (pts) with Leukemia.

G. Rosner, J. Issa, H. Kantarjian, 2004 .

Splenectomy in patients with myeloproliferative neoplasms: efficacy, complications and impact on survival and transformation

H. Kantarjian, R. Pollock, J. Cortes, 2014, Leukemia & lymphoma.

The Rationale for Immunotherapy in Myeloproliferative Neoplasms

S. Verstovsek, L. Masarová, P. Bose, 2019, Current Hematologic Malignancy Reports.

Polycythemia vera and essential thrombocythemia

S. Verstovsek, L. Falchi, 2018 .

Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet

M. Griesshammer, T. Barbui, S. Verstovsek, 2018, Leukemia.

The burden of fatigue and quality of life in myeloproliferative disorders (MPDs)

J. Sloan, S. Verstovsek, M. Wadleigh, 2007, Cancer.

Morphologic and Molecular Characteristics of De Novo AML With JAK2 V617F Mutation.

Z. Estrov, S. Verstovsek, R. Kanagal-Shamanna, 2017, Journal of the National Comprehensive Cancer Network : JNCCN.

Phase I clinical, pharmacokinetic, and pharmacodynamic study of the Akt-inhibitor triciribine phosphate monohydrate in patients with advanced hematologic malignancies.

H. Kantarjian, G. Garcia-Manero, S. Verstovsek, 2013, Leukemia research.

Use of all-trans retinoic acid plus arsenic trioxide as an alternative to chemotherapy in untreated acute promyelocytic leukemia.

E. Estey, H. Kantarjian, G. Garcia-Manero, 2006, Blood.

Long-Term Efficacy and Safety (5 Years) in RESPONSE, a Phase 3 Study Comparing Ruxolitinib (rux) with Best Available Therapy (BAT) in Hydroxyurea (HU)-Resistant/Intolerant Patients (pts) with Polycythemia Vera (PV)

M. Griesshammer, S. Verstovsek, M. Hino, 2018, Blood.

PRM-151 in Myelofibrosis: Efficacy and Safety in an Open Label Extension Study

Z. Estrov, T. Manshouri, S. Verstovsek, 2018, Blood.

Updated Results of Phase 2 Study of Ruxolitinib in Combination with 5-Azacitidine in Patients with Myelofibrosis

Z. Estrov, H. Kantarjian, G. Garcia-Manero, 2018, Blood.

Safety and Efficacy of Combined Ruxolitinib and Thalidomide in Patients with Myelofibrosis: Initial Results of a Phase II Study

S. Devlin, S. Verstovsek, T. Kadia, 2018, Blood.

Results from the 208-Week (4-Year) Follow-up of RESPONSE Trial, a Phase 3 Study Comparing Ruxolitinib (Rux) with Best Available Therapy (BAT) for the Treatment of Polycythemia Vera (PV)

M. Griesshammer, S. Verstovsek, M. Hino, 2017 .

A phase 2 study of ruxolitinib, an oral JAK1 and JAK2 inhibitor, in patients with advanced polycythemia vera who are refractory or intolerant to hydroxyurea

M. Cazzola, T. Barbui, H. Kantarjian, 2013, Cancer.

Concomitant multiple sclerosis and polycythemia vera successfully treated with glatiramer acetate

S. Verstovsek, M. Lucijanić, M. Skelin, 2022, Annals of Hematology.

Increased likelihood of post-polycythemia vera myelofibrosis in Ph-negative MPN patients with chromosome 12 abnormalities.

H. Kantarjian, J. Cortes, S. Verstovsek, 2015, Leukemia research.

Chemoimmunotherapy with a modified hyper-CVAD and rituximab regimen improves outcome in de novo Philadelphia chromosome-negative precursor B-lineage acute lymphoblastic leukemia.

M. Andreeff, H. Kantarjian, G. Garcia-Manero, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Novel BET protein Proteolysis Targeting Chimera (BET-PROTAC) exerts superior lethal activity than Bromodomain Inhibitor (BETi) against post-myeloproliferative Neoplasm (MPN) Secondary (s) AML Cells

P. Qiu, K. Rajapakshe, C. Coarfa, 2016, Leukemia.

A Phase 1/2 Study of INCB000928 As Monotherapy or in Combination with Ruxolitinib in Patients with Anemia Due to Myelofibrosis (INCB 00928-104)

S. Verstovsek, J. Gotlib, S. Oh, 2020 .

Chemoimmunotherapy with hyper‐CVAD plus rituximab for the treatment of adult Burkitt and Burkitt‐type lymphoma or acute lymphoblastic leukemia

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2006, Cancer.

Changes associated with the development of resistance to imatinib (STI571) in two leukemia cell lines expressing p210 Bcr/Abl protein

M. Andreeff, H. Kantarjian, S. Verstovsek, 2004, Cancer.

Mutation in the ATP-binding pocket of the ABL kinase domain in an STI571-resistant BCR/ABL-positive cell line.

H. Kantarjian, S. Verstovsek, M. Beran, 2002, Cancer research.

Genetic analysis of transforming events that convert chronic myeloproliferative neoplasms to leukemias.

O. Abdel-Wahab, A. Heguy, R. Levine, 2010, Cancer research.

A phase 1/2 study of ruxolitinib and decitabine in patients with post-myeloproliferative neoplasm acute myeloid leukemia

Z. Estrov, H. Kantarjian, G. Garcia-Manero, 2020, Leukemia.

A phase 2 study of pracinostat combined with ruxolitinib in patients with myelofibrosis

H. Kantarjian, S. Verstovsek, E. Jabbour, 2019, Leukemia & lymphoma.

Prognosis of Primary Myelofibrosis in the Genomic Era.

S. Verstovsek, P. Bose, 2016, Clinical lymphoma, myeloma & leukemia.

Correlation of mutation profile and response in patients with myelofibrosis treated with ruxolitinib.

H. Kantarjian, J. Cortes, T. Manshouri, 2015, Blood.

Phase II Study of Dasatinib in Philadelphia Chromosome–Negative Acute and Chronic Myeloid Diseases, Including Systemic Mastocytosis

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2008, Clinical Cancer Research.

A novel translocation t(3;21)(p21;q22) in acute myelogenous leukemia preceding a late-appearing Philadelphia chromosome

H. Kantarjian, J. Cortes, A. Quintás-Cardama, 2006, Leukemia.

Survival Advantage with Imatinib Mesylate Therapy in Chronic-Phase Chronic Myelogenous Leukemia (CML-CP) after IFN-α Failure and in Late CML-CP, Comparison with Historical Controls

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2004, Clinical Cancer Research.

Imatinib mesylate therapy improves survival in patients with newly diagnosed Philadelphia chromosome‐positive chronic myelogenous leukemia in the chronic phase

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2003, Cancer.

Novel approaches in the treatment of systemic mastocytosis

H. Kantarjian, J. Cortes, A. Quintás-Cardama, 2006, Cancer.

Inhibition of mammary carcinoma cell proliferation in vitro and tumor growth in vivo by bee venom.

S. Verstovsek, L. Šver, I. Basic, 2003, Toxicon : official journal of the International Society on Toxinology.

Frequency and clinical significance of BCR-ABL mutations in patients with chronic myeloid leukemia treated with imatinib mesylate

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2006, Leukemia.

Janus kinase inhibitors for the treatment of myeloproliferative neoplasias and beyond

H. Kantarjian, J. Cortes, A. Quintás-Cardama, 2011, Nature Reviews Drug Discovery.

SMAC mimetics as potential cancer therapeutics in myeloid malignancies

S. Verstovsek, N. Pemmaraju, B. Carter, 2019, British journal of haematology.

Phase 2 study of CEP-701, an orally available JAK2 inhibitor, in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis.

Z. Estrov, H. Kantarjian, G. Garcia-Manero, 2010, Blood.

Bortezomib therapy in myelofibrosis: a phase II clinical trial

S. Verstovsek, R. Mesa, A. Tefferi, 2008, Leukemia.

A phase II study of 5-azacitidine for patients with primary and post-essential thrombocythemia/polycythemia vera myelofibrosis

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2008, Leukemia.

INCB018424, an Oral, Selective JAK2 Inhibitor, Shows Significant Clinical Activity in a Phase I/II Study in Patients with Primary Myelofibrosis (PMF) and Post Polycythemia Vera/Essential Thrombocythemia Myelofibrosis (Post-PV/ET MF).

H. Kantarjian, J. Cortes, S. Verstovsek, 2007 .

Phase II Study of CEP701, an Orally Available JAK2 Inhibitor, in Patients with Primary Myelofibrosis and Post Polycythemia Vera/Essential Thrombocythemia Myelofibrosis.

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2007 .

What is next beyond janus kinase 2 inhibitors for primary myelofibrosis?

S. Verstovsek, F. P. Santos, 2013, Current opinion in hematology.

10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial.

J. Welch, M. Konopleva, Z. Estrov, 2020, The Lancet. Haematology.

Analysis of the impact of imatinib mesylate therapy on the prognosis of patients with Philadelphia chromosome–positive chronic myelogenous leukemia treated with interferon‐α regimens for early chronic phase

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2003, Cancer.

Treatment of Philadelphia chromosome–positive chronic myelogenous leukemia with weekly polyethylene glycol formulation of interferon‐alpha‐2b and low‐dose cytosine arabinoside

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2003, Cancer.

Imatinib mesylate therapy may overcome the poor prognostic significance of deletions of derivative chromosome 9 in patients with chronic myelogenous leukemia.

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2005, Blood.

Phase II study of low-dose decitabine in patients with chronic myelogenous leukemia resistant to imatinib mesylate.

J. Issa, J. Jelinek, H. Kantarjian, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Neutrophilic‐chronic myeloid leukemia

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2002, Cancer.

Mammalian target of rapamycin inhibition as therapy for hematologic malignancies

S. Verstovsek, F. Giles, A. Panwalkar, 2004, Cancer.

GLI1 activates pro-fibrotic pathways in myelofibrosis fibrocytes

Z. Estrov, T. Manshouri, S. Verstovsek, 2022, Cell Death & Disease.

Phase II evaluation of IPI-926, an oral Hedgehog inhibitor, in patients with myelofibrosis

J. Kutok, H. Kantarjian, J. Cortes, 2015, Leukemia & lymphoma.

A potential role of ruxolitinib in leukemia

S. Verstovsek, F. Ravandi, H. Kantarjian, 2011, Expert opinion on investigational drugs.

Plasma hepatocyte growth factor is a prognostic factor in patients with acute myeloid leukemia but not in patients with myelodysplastic syndrome

E. Estey, Z. Estrov, T. Manshouri, 2000, Leukemia.

Systemic mastocytosis with associated clonal hematological non‐mast cell lineage disease: Clinical significance and comparison of chomosomal abnormalities in SM and AHNMD components

S. Verstovsek, L. Medeiros, C. Bueso-Ramos, 2013, American journal of hematology.

Investigational histone deacetylase inhibitors (HDACi) in myeloproliferative neoplasms

S. Verstovsek, P. Bose, 2016, Expert opinion on investigational drugs.

Dual PI3K/AKT/mTOR Inhibitor BEZ235 Synergistically Enhances the Activity of JAK2 Inhibitor against Cultured and Primary Human Myeloproliferative Neoplasm Cells

K. Bhalla, T. Manshouri, S. Verstovsek, 2013, Molecular Cancer Therapeutics.

Molecular Pathways: JAK/STAT Pathway: Mutations, Inhibitors, and Resistance

A. Quintás-Cardama, S. Verstovsek, A. Quintás-Cardama, 2013, Clinical Cancer Research.

Therapy with JAK2 inhibitors for myeloproliferative neoplasms.

S. Verstovsek, F. P. Santos, 2012, Hematology/oncology clinics of North America.

Experimental therapeutics for patients with myeloproliferative neoplasias

H. Kantarjian, J. Cortes, A. Quintás-Cardama, 2011, Cancer.

BCR-ABL1-positive CML and BCR-ABL1-negative chronic myeloproliferative disorders: some common and contrasting features

G. Daley, A. Green, W. Vainchenker, 2008, Leukemia.

Potential limitations of diagnostic standard codes to distinguish polycythemia vera and secondary erythrocytosis

S. Verstovsek, Eric M Fountain, C. Rojas-Hernandez, 2021, Scientific Reports.

JAK2 inhibitors: what's the true therapeutic potential?

S. Verstovsek, F. P. Santos, 2011, Blood reviews.

Therapeutic potential of JAK2 inhibitors.

S. Verstovsek, 2009, Hematology. American Society of Hematology. Education Program.

MYC protein expression is an important prognostic factor in acute myeloid leukemia

Z. Estrov, M. Andreeff, K. Bhalla, 2019, Leukemia & lymphoma.

The Role of JAK Pathway Dysregulation in the Pathogenesis and Treatment of Acute Myeloid Leukemia

H. Kantarjian, S. Verstovsek, F. Ravandi, 2012, Clinical Cancer Research.

Immunotherapy and Immunomodulation in Myeloproliferative Neoplasms.

S. Verstovsek, N. Pemmaraju, N. Chen, 2021, Hematology/oncology clinics of North America.

Effect of Ruxolitinib On the Incidence of Splenectomy in Patients with Myelofibrosis: A Retrospective Analysis of Data From Ruxolitinib Clinical Trials.

H. Kantarjian, S. Verstovsek, R. Mesa, 2012 .

Advances and controversies in the diagnosis, pathogenesis, and treatment of systemic mastocytosis

A. Quintás-Cardama, S. Verstovsek, N. Jain, 2011, Cancer.

Imatinib effect on growth and signal transduction in polycythemia vera.

W. Vainchenker, J. Cortes, T. Manshouri, 2007, Experimental hematology.

Mutational profiling in myelofibrosis: implications for management

S. Verstovsek, P. Bose, 2019, International Journal of Hematology.

Ongoing Clinical Trials in Myeloproliferative Neoplasms

S. Verstovsek, F. P. Santos, 2012 .

Long-Term Follow up and Optimized Dosing Regimen of INCB018424 in Patients with Myelofibrosis: Durable Clinical, Functional and Symptomatic Responses with Improved Hematological Safety.

Z. Estrov, H. Kantarjian, S. Verstovsek, 2009 .

Characterization of JAK2 V617F Allele Burden in Advanced Myelofibrosis (MF) Patients: No Change in V617F:WT JAK2 Ratio in Patients with High Allele Burdens despite Profound Clinical Improvement Following Treatment with the JAK Inhibitor, INCB018424

H. Kantarjian, S. Verstovsek, A. Tefferi, 2008 .

Phase 1/2 study of the combination of 5-aza-2'-deoxycytidine with valproic acid in patients with leukemia.

Michael Rytting, Jorge Cortes, Guillermo Garcia-Manero, 2006, Blood.

Final Results of a Phase I Study of the Histone Deacetylase Inhibitor Vorinostat (Suberoyanilide Hydroxamic Acid, SAHA), in Patients with Leukemia and Myelodysplastic Syndrome.

J. Issa, M. Andreeff, H. Kantarjian, 2005 .

Thalidomide therapy for myelofibrosis with myeloid metaplasia

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2006, Cancer.

A critical appraisal of conventional and investigational drug therapy in patients with hypereosinophilic syndrome and clonal eosinophilia

H. Kantarjian, A. Quintás-Cardama, S. Verstovsek, 2007, Cancer.

Phase 2 clinical and pharmacologic study of clofarabine in patients with refractory or relapsed acute leukemia.

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2003, Blood.

Clinical relevance of VEGF receptors 1 and 2 in patients with chronic myelogenous leukemia.

H. Kantarjian, J. Cortes, T. Manshouri, 2003, Leukemia research.

WP1066, a Novel JAK2 Inhibitor, Suppresses Proliferation and Induces Apoptosis in Erythroid Human Cells Carrying the JAK2 V617F Mutation

Z. Estrov, D. Harris, H. Kantarjian, 2008, Clinical Cancer Research.

Polycythemia vera is not initiated by JAK2V617F mutation.

J. Jelinek, S. Verstovsek, S. Swierczek, 2007, Experimental hematology.

High-Dose (HD) Imatinib Provides Better Responses in Patients with Untreated Early Chronic Phase (CP) CML.

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2006 .

Significance of angiogenin plasma concentrations in patients with acute myeloid leukaemia and advanced myelodysplastic syndrome

H. Kantarjian, T. Manshouri, S. Verstovsek, 2001, British journal of haematology.

Phase II study of low‐dose decitabine in combination with imatinib mesylate in patients with accelerated or myeloid blastic phase of chronic myelogenous leukemia

J. Issa, Y. Oki, H. Kantarjian, 2007, Cancer.

Prognostic significance of CD20 expression in adults with de novo precursor B-lineage acute lymphoblastic leukemia.

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2009, Blood.

precursor B-lineage acute lymphoblastic leukemia Prognostic significance of CD 20 expression in adults with de novo

H. Kantarjian, J. Cortes, S. Verstovsek, 2009 .

Prognostic significance of CD 20 expression in adults with de novo precursor B-lineage acute lymphoblastic leukemia

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2009 .

Outcome of patients with acute myelogenous leukemia after second salvage therapy

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2005, Cancer.

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2004 .

Effect of circulating blasts at time of complete remission on subsequent relapse-free survival time in newly diagnosed AML.

P. Thall, E. Estey, H. Kantarjian, 2003, Blood.

A randomized study of clofarabine versus clofarabine plus low-dose cytarabine as front-line therapy for patients aged 60 years and older with acute myeloid leukemia and high-risk myelodysplastic syndrome.

Z. Estrov, H. Kantarjian, G. Garcia-Manero, 2008, Blood.

EXEL-0862, a novel tyrosine kinase inhibitor, induces apoptosis in vitro and ex vivo in human mast cells expressing the KIT D816V mutation.

H. Kantarjian, J. Cortes, T. Manshouri, 2007, Blood.

Comprehensive kinase profile of pacritinib, a nonmyelosuppressive Janus kinase 2 inhibitor

Haiching Ma, S. Verstovsek, R. Mesa, 2016, Journal of experimental pharmacology.

Clinical relevance of vascular endothelial growth factor receptors 1 and 2 in acute myeloid leukaemia and myelodysplastic syndrome

H. Kantarjian, J. Cortes, T. Manshouri, 2002, British journal of haematology.

Patient Characteristics and Outcomes in Adolescents and Young Adults (AYA) With Acute Myeloid Leukemia (AML).

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2016, Clinical lymphoma, myeloma & leukemia.

Progressive burden of myelofibrosis in untreated patients: assessment of patient-reported outcomes in patients randomized to placebo in the COMFORT-I study.

A. Shields, S. Verstovsek, R. Mesa, 2013, Leukemia research.

New approaches in the treatment of myelofibrosis

H. Kantarjian, S. Verstovsek, B. Hennessy, 2005, Cancer.

Treated secondary acute myeloid leukemia: a distinct high-risk subset of AML with adverse prognosis.

M. Konopleva, Z. Estrov, M. Andreeff, 2017, Blood advances.

Primary myelofibrosis associated glomerulopathy: significant improvement after therapy with ruxolitinib

S. Verstovsek, M. Abdelrahim, A. Rajasekaran, 2015, BMC Nephrology.

Renal complications of primary myelofibrosis

S. Verstovsek, M. Abdelrahim, W. Glass, 2018, Leukemia & lymphoma.

Ruxolitinib therapy is associated with improved renal function in patients with primary myelofibrosis

S. Verstovsek, M. Abdelrahim, S. Pierce, 2019, Annals of Hematology.

Impact of bone marrow pathology on the clinical management of Philadelphia chromosome-negative myeloproliferative neoplasms.

S. Verstovsek, R. Hasserjian, O. Pozdnyakova, 2015, Clinical lymphoma, myeloma & leukemia.

A phase II study of decitabine and gemtuzumab ozogamicin in newly diagnosed and relapsed acute myeloid leukemia and high-risk myelodysplastic syndrome

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2016, Leukemia.

Stimulation of the B-cell receptor activates the JAK2/STAT3 signaling pathway in chronic lymphocytic leukemia cells.

Z. Estrov, D. Harris, S. Verstovsek, 2014, Blood.

Janus kinase 2 variants associated with the transformation of myeloproliferative neoplasms into acute myeloid leukemia

M. Konopleva, M. Andreeff, H. Kantarjian, 2019, Cancer.

Eradication of minimal residual disease in hairy cell leukemia.

H. Kantarjian, S. Verstovsek, Xuelin Huang, 2006, Blood.

Phase II study of cladribine (2CDA) followed by rituximab for eradication of minimal residual disease (MRD) in hairy cell leukemia (HCL)

S. Verstovsek, S. O'brien, J. Jorgensen, 2005 .

Increased telomerase activity is associated with shorter survival in patients with chronic phase chronic myeloid leukemia

H. Kantarjian, J. Cortes, T. Manshouri, 2003, Cancer.

Targeted next-generation sequencing identifies a subset of idiopathic hypereosinophilic syndrome with features similar to chronic eosinophilic leukemia, not otherwise specified

P. Cin, A. Bagg, W. Tam, 2016, Modern Pathology.

How I manage anemia related to myelofibrosis and its treatment regimens

S. Verstovsek, 2023, Annals of Hematology.

Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phase 3 study

Angela G. Fleischman, A. Salar, S. Verstovsek, 2023, The Lancet.

Anemia in myelofibrosis: current and emerging treatment options.

S. Verstovsek, R. Mesa, A. Vannucchi, 2022, Critical reviews in oncology/hematology.

Use of the Functional Assessment of Cancer Therapy--anemia in persons with myeloproliferative neoplasm-associated myelofibrosis and anemia.

S. Verstovsek, R. Gale, R. Mesa, 2014, Clinical therapeutics.

Proposed criteria for the diagnosis of post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a consensus statement from the international working group for myelofibrosis research and treatment

P. Campbell, S. Verstovsek, R. Mesa, 2008, Leukemia.

Comorbidities predict worse prognosis in patients with primary myelofibrosis

S. Verstovsek, K. Newberry, S. Pierce, 2014, Cancer.

Myelofibrosis osteoclasts are clonal and functionally impaired.

Z. Estrov, A. Multani, T. Manshouri, 2019, Blood.

Adult acute megakaryocytic leukemia: an analysis of 37 patients treated at M.D. Anderson Cancer Center.

E. Estey, Y. Oki, H. Kantarjian, 2006, Blood.

Effective treatment of acute promyelocytic leukemia with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin.

E. Estey, Z. Estrov, H. Kantarjian, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Role of neoplastic monocyte-derived fibrocytes in primary myelofibrosis

C. Creighton, Z. Estrov, D. Harris, 2016, The Journal of experimental medicine.

Pelabresib (CPI-0610) Combined with Ruxolitinib for JAK Inhibitor Treatment-Naïve Patients with Myelofibrosis: Durability of Response and Safety Beyond Week 24

S. Verstovsek, M. Talpaz, A. Patriarca, 2022, Blood.

Pelabresib (CPI-0610) As Add-on to Ruxolitinib in Myelofibrosis: Durability of Response and Safety Beyond Week 24 in the Phase 2 MANIFEST Study

S. Verstovsek, M. Talpaz, A. Vannucchi, 2022, Blood.

MPN-478 MOMENTUM: Phase 3 Randomized Study of Momelotinib (MMB) versus Danazol (DAN) in Symptomatic and Anemic Myelofibrosis (MF) Patients Previously Treated With a JAK Inhibitor.

S. Verstovsek, R. Donahue, R. Mesa, 2022, Clinical lymphoma, myeloma & leukemia.

A Phase 1/2 Study of Single Agent Tagraxofusp, a First-in-Class CD123-Targeted Therapy, in Patients with Myelofibrosis That Is Relapsed/Refractory Following JAK Inhibitor Therapy

S. Verstovsek, C. Brooks, A. Tefferi, 2021, Blood.

Potential Disease-Modifying Activity of Navtemadlin (KRT-232), a First-in-Class MDM2 Inhibitor, Correlates with Clinical Benefits in Relapsed/Refractory Myelofibrosis (MF)

J. Hernández-Rivas, S. Verstovsek, C. Krejsa, 2021, Blood.

A pooled analysis of overall survival in COMFORT-I and COMFORT-II, 2 randomized phase III trials of ruxolitinib for the treatment of myelofibrosis

Francisco Cervantes, Wei Peng, Jason Gotlib, 2015, Haematologica.

Highly reproducible detection and semi-quantification of telomerase activity.

E. Estey, T. Manshouri, S. Verstovsek, 2001, BioTechniques.

A prognostic model for survival in chronic lymphocytic leukaemia based on p53 expression

P. Thall, H. Kantarjian, J. Cortes, 2003, British journal of haematology.

IClinicalTrial of Darinaparsin in Patients with Refractory SolidTumors

C. Ng, R. Kurzrock, S. Verstovsek, 2009 .

JAK2 p.V617F detection and allele burden measurement in peripheral blood and bone marrow aspirates in patients with myeloproliferative neoplasms.

H. Kantarjian, J. Cortes, S. Verstovsek, 2013, Blood.

Long-term outcome of acute promyelocytic leukemia treated with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab.

E. Estey, M. Konopleva, Z. Estrov, 2017, Blood.

Use of All-Transretinoic Acid (ATRA) + Arsenic Trioxide (ATO) To Eliminate or Minimize Use of Chemotherapy (CT) in Untreated Acute Promyelocytic Leukemia (APL).

E. Estey, H. Kantarjian, G. Garcia-Manero, 2004 .

SU5416, a small molecule tyrosine kinase receptor inhibitor, has biologic activity in patients with refractory acute myeloid leukemia or myelodysplastic syndromes.

H. Kantarjian, A. Stopeck, J. Cortes, 2003, Blood.

Quantitative profiling of codon 816 KIT mutations can aid in the classification of systemic mast cell disease

S. Verstovsek, C. Bueso-Ramos, B. Barkoh, 2007, Leukemia.

Precision immunotherapy, mutational landscape, and emerging tools to optimize clinical outcomes in patients with classical myeloproliferative neoplasms

O. Abdel-Wahab, T. Lion, S. Verstovsek, 2018, Hematological oncology.

Results of the Persist-2 Phase 3 Study of Pacritinib (PAC) Versus Best Available Therapy (BAT), Including Ruxolitinib (RUX), in Patients (pts) with Myelofibrosis (MF) and Platelet Counts <100,000/µl

S. Verstovsek, R. Hoffman, R. Mesa, 2016 .

Clinical features and outcome of patients with poor-prognosis myelofibrosis based on platelet count <50 x 109/L: A single-center experience in 1100 myelofibrosis patients.

H. Kantarjian, J. Cortes, S. Verstovsek, 2016 .

Revised response criteria for myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report.

Francisco Cervantes, Giovanni Barosi, Juergen Thiele, 2013, Blood.

Improvement of overall and failure-free survival in stage IV follicular lymphoma: 25 years of treatment experience at The University of Texas M.D. Anderson Cancer Center.

G. Ayers, S. Verstovsek, P. Mclaughlin, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

New Therapeutic Approaches in Polycythemia Vera.

S. Verstovsek, K. Newberry, L. Falchi, 2015, Clinical lymphoma, myeloma & leukemia.

and bone marrow aspirates in patients with myeloproliferative neoplasms JAK2 p.V617F detection and allele burden measurement in peripheral blood

H. Kantarjian, J. Cortes, S. Verstovsek, 2013 .

The haematopoietic cell transplantation comorbidity index score is predictive of early death and survival in patients over 60 years of age receiving induction therapy for acute myeloid leukaemia.

H. Kantarjian, J. Cortes, S. Verstovsek, 2007, British journal of haematology.

Lenalidomide in High-Risk Myelodysplastic Syndrome and Acute Myelogenous Leukemia Associated with Chromosome 5 Abnormalities.

Z. Estrov, H. Kantarjian, G. Garcia-Manero, 2007 .

Characteristics and outcomes of older patients with secondary acute myeloid leukemia according to treatment approach

M. Konopleva, K. Bhalla, H. Kantarjian, 2017, Cancer.

Adaptive randomized study of idarubicin and cytarabine alone or with interleukin-11 as induction therapy in patients aged 50 or above with acute myeloid leukemia or high-risk myelodysplastic syndromes.

E. Estey, H. Kantarjian, G. Garcia-Manero, 2005, Leukemia research.

Efficacy and safety of pegylated interferon alpha-2a in patients with essential thrombocythemia (ET) and polycythemia vera (PV): results of a phase 2 study after a 7-year median follow-up

M. Konopleva, Z. Estrov, H. Kantarjian, 2017, The Lancet. Haematology.

STAT3 induces the expression of GLI1 in chronic lymphocytic leukemia cells

Z. Estrov, D. Harris, T. Manshouri, 2021, Oncotarget.

Masitinib for treatment of severely symptomatic indolent systemic mastocytosis: a randomised, placebo-controlled, phase 3 study

R. Gaillard, J. Kinet, S. Verstovsek, 2017, The Lancet.

Myeloproliferative Neoplasms With Calreticulin Mutations Exhibit Distinctive Morphologic Features.

S. Verstovsek, M. Routbort, K. Patel, 2016, American journal of clinical pathology.

Thymic anti‐tumor effectors in mice cured of lymphoma by cyclophosphamide plus TNF‐α therapy: Phenotypic and functional characterization up to 20 months after initial tumor inoculation

M. J. Ehrke, S. Verstovsek, J. M. Meer, 1998, International journal of cancer.

A multimodality work‐up of patients with Hypereosinophilia

W. Tam, S. Verstovsek, L. Medeiros, 2018, American journal of hematology.

Acute myeloid leukemia after myelodysplastic syndrome and failure of therapy with hypomethylating agents: an emerging entity with a poor prognosis.

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2013, Clinical lymphoma, myeloma & leukemia.

Hyper-CVAD regimen in combination with ofatumumab as frontline therapy for adults with Philadelphia chromosome-negative B-cell acute lymphoblastic leukaemia: a single-arm, phase 2 trial.

C. Mullighan, M. Konopleva, H. Kantarjian, 2020, The Lancet. Haematology.

A Phase I Study of XL019, a Selective JAK2 Inhibitor, in Patients with Primary Myelofibrosis and Post-Polycythemia Vera/Essential Thrombocythemia Myelofibrosis.

D. Gilliland, H. Kantarjian, S. Verstovsek, 2007 .

Phase II trial of CPX-351 in patients with acute myeloid leukemia at high risk for induction mortality

Z. Estrov, H. Kantarjian, G. Garcia-Manero, 2020, Leukemia.

How we diagnose and treat WHO-defined systemic mastocytosis in adults

S. Verstovsek, A. Tefferi, A. Pardanani, 2008, Haematologica.

Allogeneic stem cell transplantation for myelofibrosis with leukemic transformation.

S. Verstovsek, B. Andersson, C. Bueso-Ramos, 2010, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Long-Term Follow-Up after Frontline Therapy with the Hyper-CVAD and Imatinib Mesylate Regimen in Adults with Philadelphia (Ph) Positive Acute Lymphocytic Leukemia (ALL).

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2007 .

Acute lymphoblastic leukemia secondary to myeloproliferative neoplasms or after lenalidomide exposure

S. Verstovsek, Y. Huh, P. Bose, 2017, Clinical case reports.

Characteristics and outcomes of patients with multiple myeloma who develop therapy-related myelodysplastic syndrome, chronic myelomonocytic leukemia, or acute myeloid leukemia.

V. Baladandayuthapani, H. Kantarjian, G. Garcia-Manero, 2015, Clinical lymphoma, myeloma & leukemia.

Outcomes of adults with relapsed or refractory Burkitt and high‐grade B‐cell leukemia/lymphoma

Z. Estrov, H. Kantarjian, G. Garcia-Manero, 2017, American journal of hematology.

A clinical trial for patients with acute myeloid leukemia or myelodysplastic syndromes not eligible for standard clinical trials

M. Konopleva, Z. Estrov, H. Kantarjian, 2017, Leukemia.

Arsenic derivatives in hematologic malignancies: a role beyond acute promyelocytic leukemia?

A. Quintás-Cardama, S. Verstovsek, E. Freireich, 2006, Hematological oncology.

Development of Varicella-Zoster virus infection in patients with chronic myelogenous leukemia treated with imatinib mesylate.

H. Kantarjian, J. Cortes, S. Verstovsek, 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

Optimizing the Conditioning Regimen for HCT in Myelofibrosis: Long-term Results of a Prospective Phase II Clinical Trial.

E. Shpall, S. Verstovsek, B. Andersson, 2020, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients with Myelofibrosis with Prior Exposure to Janus Kinase 1/2 Inhibitors.

M. Arcasoy, S. Verstovsek, D. Mclornan, 2016, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

AMN107, a novel aminopyrimidine inhibitor of p190 Bcr‐Abl activation and of in vitro proliferation of Philadelphia‐positive acute lymphoblastic leukemia cells

Z. Estrov, H. Kantarjian, J. Cortes, 2005, Cancer.

Final results of a phase 2 clinical trial of LCL161, an oral SMAC mimetic for patients with myelofibrosis.

M. Konopleva, Z. Estrov, G. Garcia-Manero, 2021, Blood Advances.

Pan-Myeloid Leukemia Analysis: Machine Learning-Based Approach to Predict Phenotype and Clinical Outcomes Using Mutation Data

P. A. Futreal, S. Ogawa, Jianhua Zhang, 2018, Blood.

The JAK Inhibitor, INCB018424, Demonstrates Durable and Marked Clinical Responses in Primary Myelofibrosis (PMF) and Post-Polycythemia/Essential Thrombocythemia Myelofibrosis (Post PV/ETMF).

H. Kantarjian, J. Cortes, S. Verstovsek, 2008 .

A Rare Case of Primary Myelofibrosis in a 14-Year-Old Patient With Congenital Asplenia.

S. Verstovsek, Maliha Khan, C. Yin, 2017, Journal of pediatric hematology/oncology.

Analysis of outcomes in adolescents and young adults with chronic myelogenous leukemia treated with upfront tyrosine kinase inhibitor therapy

H. Kantarjian, J. Cortes, A. Quintás-Cardama, 2012, Haematologica.

Advanced systemic mastocytosis: from molecular and genetic progress to clinical practice

H. Kluin-Nelemans, S. Verstovsek, T. George, 2016, Haematologica.

Consensus Opinion on Allogeneic Hematopoietic Cell Transplantation in Advanced Systemic Mastocytosis.

H. Deeg, M. Perales, H. Kluin-Nelemans, 2016, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Myeloproliferative neoplasms, version 2.2018 featured Updates to the NCCN guidelines

E. Ranheim, K. Gregory, C. Fletcher, 2017 .

Phase I Dose-Escalation Trial of SB1518, a Novel JAK2/FLT3 Inhibitor, in Acute and Chronic Myeloid Diseases, Including Primary or Post-Essential Thrombocythemia/ Polycythemia Vera Myelofibrosis.

H. Deeg, J. Wood, Z. Estrov, 2009 .

In vitro effects of STI 571‐containing drug combinations on the growth of Philadelphia‐positive chronic myelogenous leukemia cells

H. Kantarjian, S. Verstovsek, M. Keating, 2002, Cancer.

The Combination of Ruxolitinib (RUX) with Decitabine (DAC) in Patients (Pts) with Post-Myeloproliferative Neoplasm Acute Myeloid Leukemia (post-MPN AML): Interim Report of a Phase I/II Trial

Z. Estrov, H. Kantarjian, G. Garcia-Manero, 2017 .

Phase I/II Study of Ruxolitinib (RUX) with Decitabine (DAC) in Patients with Post-Myeloproliferative Neoplasm Acute Myeloid Leukemia (post-MPN AML): Phase I Results

Z. Estrov, H. Kantarjian, G. Garcia-Manero, 2016 .

Decitabine therapy for myeloproliferative neoplasm in accelerated (MPN-AP) or blastic (acute myeloid leukemia; MPN-AML) phase.

H. Kantarjian, J. Cortes, S. Verstovsek, 2014 .

Bone marrow findings in blast phase of polycythemia vera

S. Verstovsek, L. Medeiros, C. Bueso-Ramos, 2018, Annals of Hematology.

Pomalidomide Therapy in Anemic Patients with Myelofibrosis: Results from a Phase-2 Randomized Multicenter Study

H. Deeg, H. Kantarjian, S. Verstovsek, 2008 .

JAK2 Inhibitors for Therapy of Myeloproliferative Neoplasms

S. Verstovsek, F. P. Santos, 2011 .

Biology and Clinical Management of Myeloproliferative Neoplasms and Development of the JAK Inhibitor Ruxolitinib

S. Verstovsek, J. Mascarenhas, S Verstovsek, 2012, Current medicinal chemistry.

Aberrant myeloid maturation identified by flow cytometry in primary myelofibrosis.

S. Verstovsek, J. Jorgensen, P. Lin, 2010, American journal of clinical pathology.

Advanced systemic mastocytosis: the impact of KIT mutations in diagnosis, treatment, and progression

S. Verstovsek, 2013, European journal of haematology.

International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) & European Competence Network on Mastocytosis (ECNM) consensus response criteria in advanced systemic mastocytosis.

A. Órfão, H. Kluin-Nelemans, S. Verstovsek, 2013, Blood.

Discrepancy in diagnosis of primary myelofibrosis between referral and tertiary care centers.

H. Kantarjian, J. Cortes, S. Verstovsek, 2014, Leukemia research.

A phase 1 study of the Janus kinase 2 (JAK2)V617F inhibitor, gandotinib (LY2784544), in patients with primary myelofibrosis, polycythemia vera, and essential thrombocythemia.

M. Salama, S. Verstovsek, R. Mesa, 2017, Leukemia research.

Assessing efficacy in myelofibrosis treatment: a focus on JAK inhibition

S. Verstovsek, R. Komrokji, 2012, Expert review of hematology.

Acute pulmonary failure during remission induction chemotherapy in adults with acute myeloid leukemia or high‐risk myelodysplastic syndrome

H. Kantarjian, S. Verstovsek, F. Ravandi, 2009, Cancer.

Jumping Translocations in Myeloid Malignancies Associated With Treatment Resistance and Poor Survival.

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2015, Clinical lymphoma, myeloma & leukemia.

Prevalence of pulmonary hypertension in myelofibrosis

Peter Y. Kim, H. Grosu, S. Faiz, 2020, Annals of Hematology.

Long-term results of a phase II trial of lenalidomide plus prednisone therapy for patients with myelofibrosis.

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2016, Leukemia research.

Dynamic model for predicting death within 12 months in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis.

H. Kantarjian, J. Cortes, S. Verstovsek, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II Study of Dasatinib (SPRYCEL™) in Philadelphia Chromosome-Negative Acute and Chronic Myeloid Diseases, Including Systemic Mastocytosis.

H. Kantarjian, G. Garcia-Manero, S. Verstovsek, 2007 .

Sensitivity of human cells bearing oncogenic mutant kit isoforms to the novel tyrosine kinase inhibitor INNO‐406

H. Kantarjian, J. Cortes, T. Manshouri, 2007, Cancer science.

Phase II Study of the Frontline Hyper-CVAD in Combination with Ofatumumab for Adult Patients (pts) with CD-20 Positive Acute Lymphoblastic Leukemia (ALL)

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2015 .

Activity of alemtuzumab in patients with CD52‐positive acute leukemia

G. Garcia-Manero, J. Cortes, S. Verstovsek, 2006, Cancer.

Triple-Negative Primary Myelofibrosis: A Bone Marrow Pathology Group Study.

A. Bagg, D. Arber, S. Verstovsek, 2023, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.

The BH3-mimetic GX15-070 induces autophagy, potentiates the cytotoxicity of carboplatin and 5-fluorouracil in esophageal carcinoma cells.

S. Verstovsek, Q. Cao, Yanli Jin, 2010, Cancer letters.

Comprehensive Kinase Profile of Pacritinib, a Non-Myelosuppressive JAK2 Kinase Inhibitor in Phase 3 Development in Primary and Post ET/PV Myelofibrosis

Haiching Ma, S. Verstovsek, R. Mesa, 2014 .

JAK2 inhibitors for myelofibrosis: why are they effective in patients with and without JAK2V617F mutation?

S. Verstovsek, F. P. Santos, 2012, Anti-cancer agents in medicinal chemistry.

US Optum Database Study in Polycythemia Vera Patients: Thromboembolic Events (TEs) with Hydroxyurea (HU) Vs Ruxolitinib Switch Therapy and Machine-Learning Model to Predict Incidence of Tes and HU Failure

S. Verstovsek, F. Heidel, M. Zuurman, 2019, Blood.

Alternate Week Administration of the Farnesyltransferase Inhibitor Tipifarnib (ZARNESTRA®, R115777) in Patients with Myelodysplastic Syndrome: Results of a Phase 1 Study.

E. Estey, R. Kurzrock, H. Kantarjian, 2005 .

Farnesyl Transferase Inhibitor (Tipifarnib, Zarnestra; Z) in Combination with Standard Chemotherapy with Idarubicin (Ida) and Cytarabine (ara-C) for Patients (pts) with Newly Diagnosed Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS).

Z. Estrov, H. Kantarjian, G. Garcia-Manero, 2005 .

Sensitive PCR‐based monitoring and early detection of relapsed JAK2 V617F myelofibrosis following transplantation

R. Luthra, S. Verstovsek, K. Patel, 2018, British journal of haematology.

A phase II trial of ruxolitinib in combination with azacytidine in myelodysplastic syndrome/myeloproliferative neoplasms

Z. Estrov, H. Kantarjian, G. Garcia-Manero, 2018, American journal of hematology.

Safety and Tolerability of Fedratinib (FEDR), an Oral Inhibitor of Janus Kinase 2 (JAK2), in Patients with Intermediate- or High-Risk Myelofibrosis (MF) Previously Treated with Ruxolitinib (RUX): Results from the Phase 3b FREEDOM Trial

H. Deeg, S. Verstovsek, R. Mesa, 2021, Blood.

A Randomized, Phase 3 Trial of Fedratinib Versus Best Available Therapy in Patients with Intermediate-2 or High-Risk Myelofibrosis Previously Treated with Ruxolitinib (FREEDOM2)

S. Verstovsek, R. Mesa, G. Barosi, 2021, Blood.

Duration of Response to Luspatercept in Patients (Pts) Requiring Red Blood Cell (RBC) Transfusions with Myelofibrosis (MF) - Updated Data from the Phase 2 ACE-536-MF-001 Study

A. Mead, S. Verstovsek, T. Gerike, 2020 .

A Multicenter Phase 1/2 Clinical Trial of Tagraxofusp, a CD123-Targeted Therapy, in Patients with Poor-Risk Primary and Secondary Myelofibrosis

S. Verstovsek, C. Brooks, M. Talpaz, 2020 .

MANIFEST-2, a Global, Phase 3, Randomized, Double-Blind, Active-Control Study of CPI-0610 and Ruxolitinib Vs. Placebo and Ruxolitinib in JAK-Inhibitor-Naive Myelofibrosis Patients

P. Trojer, S. Verstovsek, C. Harrison, 2020, Blood.

Sotatercept (ACE-011) for Anemia of Myelofibrosis: A Phase 2 Study

Z. Estrov, M. Andreeff, H. Kantarjian, 2020 .

Prognostic impact of RAS-pathway mutations in patients with myelofibrosis

M. Arcila, R. Levine, H. Kantarjian, 2019, Leukemia.

Results of a Phase II Trial of Dasatinib As Frontline Therapy for Chronic Myeloid Leukemia (CML) In Chronic Phase (CP)

E. Burton, H. Kantarjian, J. Cortes, 2011 .

Real-world treatments and thrombotic events in polycythemia vera patients in the USA

S. Gupta, S. Verstovsek, N. Pemmaraju, 2023, Annals of Hematology.

Primary Cell Experiments with TG101348, a JAK2-Selective Inhibitor, in the Presence of Myeloproliferative Disorder-Associated JAK2V617F, MPLW515L/K, and JAK2 Exon 12 Mutations.

G. Noronha, H. Kantarjian, J. Cortes, 2007 .

Characteristics and clinical significance of cytogenetic abnormalities in polycythemia vera

S. Verstovsek, L. Medeiros, C. Bueso-Ramos, 2017, Haematologica.

Phase II Study of Cladribine and Low-Dose Cytarabine (AraC) Alternating with Decitabine in Older Patients with Acute Myeloid Leukemia (AML)

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2014 .

Phase II trial of cladribine and low-dose AraC alternating with decitabine in older patients with AML.

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2014 .

Emerging translational science discoveries, clonal approaches, and treatment trends in chronic myeloproliferative neoplasms

J. Radich, T. Barbui, S. Verstovsek, 2019, Hematological oncology.

Kit Mutations: New Insights and Diagnostic Value.

S. Verstovsek, L. Falchi, 2018, Immunology and allergy clinics of North America.

JAK2V617F detection and allele burden measurement in saliva vs. peripheral blood in patients with myelofibrosis.

T. Manshouri, S. Verstovsek, Ying Zhang, 2017, Leukemia research.

Thrombotic events and mortality risk in patients with newly diagnosed polycythemia vera or essential thrombocythemia.

S. Verstovsek, N. Pemmaraju, R. Scherber, 2022, Leukemia research.

Hepatosplenic T-Cell Lymphoma: Clinical Characteristics and Treatment Outcome.

S. Verstovsek, S. O'brien, L. Kwak, 2006 .

Notch-dependent repression of miR-155 in the bone marrow niche regulates hematopoiesis in an NF-κB-dependent manner.

D. Chen, T. Manshouri, S. Verstovsek, 2014, Cell stem cell.

Secondary erythrocytosis

S. Verstovsek, N. Pemmaraju, C. Rojas-Hernandez, 2023, Expert review of hematology.

A phase II open-label study of the intravenous administration of homoharringtonine in the treatment of myelodysplastic syndrome.

Z. Estrov, H. Kantarjian, G. Garcia-Manero, 2013, European journal of cancer care.

A review of essential thrombocythemia and its complications.

S. Verstovsek, L. Masarová, R. Babakhanlou, 2023, Clinical advances in hematology & oncology : H&O.

Phase II Study of Decitabine in Combination with Imatinib Mesylate in Patients with Accelerated (AP) or Blastic Phase (BP) of Chronic Myeloid Leukemia (CML).

J. Issa, Y. Oki, H. Kantarjian, 2005 .

Hypomethylation induction in MDS after treatment with decitabine at three different doses

J. Issa, Y. Oki, H. Kantarjian, 2005 .

Clinical relevance of soluble HLA-I and beta2-microglobulin levels in non-Hodgkin's lymphoma and Hodgkin's disease.

J. Armitage, J. Vose, H. Kantarjian, 2007, Leukemia research.

Atypical cases of necrotizing sweet syndrome in patients with myelodysplastic syndrome and acute myeloid leukaemia

G. Garcia-Manero, S. Verstovsek, F. Ravandi, 2020, British journal of haematology.

Clinical Significance of Molecular Monitoring in Chronic Myeloid Leukemia (CML) in Chronic Phase (CP) with Imatinib Therapy.

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2004 .

Fedratinib Improves Myelofibrosis-related Symptoms and Health-related Quality of Life in Patients with Myelofibrosis Previously Treated with Ruxolitinib: Patient-reported Outcomes from the Phase II JAKARTA2 Trial

S. Verstovsek, R. Mesa, M. Talpaz, 2021, HemaSphere.

Patient-reported Effects of Fedratinib, an Oral, Selective Inhibitor of Janus Kinase 2, on Myelofibrosis-related Symptoms and Health-related Quality of Life in the Randomized, Placebo-controlled, Phase III JAKARTA Trial

S. Verstovsek, R. Mesa, M. Talpaz, 2021, HemaSphere.

Role of angiogenesis in chronic lymphocytic leukemia

S. Verstovsek, R. Vrhovac, A. Ferrajoli, 2006, Cancer.

SOHO State of the Art Updates and Next Questions: Novel Therapeutic Strategies in Development for Myelofibrosis.

S. Verstovsek, L. Masarová, H. Chifotides, 2023, Clinical lymphoma, myeloma & leukemia.

Evaluating ropeginterferon alfa-2b for the treatment of adults with polycythemia vera

S. Verstovsek, M. Skelin, I. Krečak, 2023, Expert review of hematology.

P1028: PTG-300 (RUSFERTIDE) TREATMENT INTERRUPTION REVERSES HEMATOLOGICAL GAINS AND RESTORES THERAPEUTIC BENEFIT ON REINITIATION IN SUBJECTS WITH POLYCYTHEMIA VERA

S. Gupta, S. Verstovsek, M. Kremyanskaya, 2022, HemaSphere.

Phase II study of vorinostat (V) in combination with idarubicin and high-dose cytarabine (IA) as front-line therapy in patients (pts) with high-risk myelodyplsatic syndrome (MDS) or acute myeloid leukemia (AML).

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2009, Journal of Clinical Oncology.

A phase 2 study of hyper-CVAD plus ofatumumab as frontline therapy in CD20+ acute lymphoblastic leukemia (ALL): Updated results.

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2018 .

Ten years after ruxolitinib approval for myelofibrosis: a review of clinical efficacy

Angela G. Fleischman, S. Verstovsek, N. Pemmaraju, 2023, Leukemia & lymphoma.

Cytopenic myelofibrosis: prevalence, relevance, and treatment

S. Verstovsek, P. Bose, P. Vachhani, 2023, Expert opinion on pharmacotherapy.

MANIFEST: Pelabresib in Combination With Ruxolitinib for Janus Kinase Inhibitor Treatment-Naïve Myelofibrosis

A. Mead, M. Salama, S. Verstovsek, 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Risk‐adjusted safety analysis of the oral JAK2/IRAK1 inhibitor pacritinib in patients with myelofibrosis

S. Verstovsek, A. Vannucchi, M. McMullin, 2022, EJHaem.

Clinical Evolution to Primary Myelofibrosis - Blast Phase: An International Working Group for Myelofibrosis Research and Treatment (IWG-MRT) Collaborative Retrospective Analysis.

S. Verstovsek, R. Mesa, J. Reilly, 2007 .

High Blast Percentage, Chromosome 17 Abnormalities and Severe Pancytopenia Predict Death within Twelve Months in Patients with Myelofibrosis.

H. Kantarjian, J. Cortes, S. Verstovsek, 2007 .

Clinical Significance of Complete Cytogenetic Response (CCyR) and Major Molecular Response (MMR) Achieved with Different Treatment Modalities Used As Frontline Therapy In Chronic Myeloid Leukemia (CML) Chronic Phase (CP)

M. Konopleva, E. Burton, H. Kantarjian, 2011 .

Potential New Therapeutic Approaches for Myelofibrosis

S. Verstovsek, H. Chifotides, 2021 .

High-dose imatinib mesylate treatment in patients (Pts) with untreated early chronic phase (CP) chronic myeloid leukemia (CML): 2.5-year follow-up.

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Bone Marrow Fibrosis Changes Do Not Correlate with Efficacy Outcomes in Myelofibrosis: Analysis of More Than 300 JAK Inhibitor-Naïve Patients Treated with Momelotinib or Ruxolitinib

A. Mead, S. Verstovsek, M. McMullin, 2022, Blood.

Safety and Efficacy of Combined Ruxolitinib and Thalidomide in Patients with Myelofibrosis: A Phase II Study

S. Devlin, S. Verstovsek, T. Kadia, 2019, Blood.

Ruxolitinib (RUX) Induced Meaningful and Directional Changes in the Bone Marrow Microenvironment of Patients with Myelofibrosis Enrolled in the COMFORT-I Study

S. Verstovsek, C. Bueso-Ramos, J. Thiele, 2019, Blood.

Characteristics of patients with myeloproliferative neoplasms with lymphoma, with or without JAK inhibitor therapy.

H. Kantarjian, S. Verstovsek, K. Patel, 2019, Blood.

A phase 2 study of ruxolitinib in combination with azacitidine in patients with myelofibrosis.

Z. Estrov, K. Bhalla, H. Kantarjian, 2018, Blood.

BOREAS: a global, phase III study of the MDM2 inhibitor navtemadlin (KRT-232) in relapsed/refractory myelofibrosis.

S. Verstovsek, A. Vannucchi, S. Koschmieder, 2022, Future oncology.

MYF3001: A Randomized Open Label, Phase 3 Study to Evaluate Imetelstat Versus Best Available Therapy in Patients with Intermediate-2 or High-Risk Myelofibrosis Relapsed/Refractory to Janus Kinase Inhibitor

S. Verstovsek, A. Vannucchi, S. Koschmieder, 2022, Blood.

Updated Results from the Momentum Phase 3 Study of Momelotinib (MMB) Versus Danazol (DAN) in Symptomatic and Anemic Myelofibrosis (MF) Patients Previously Treated with a JAK Inhibitor

S. Verstovsek, R. Donahue, A. Vannucchi, 2022, Blood.

A phase 2, multicenter, open-label study of the safety and efficacy of luspatercept in subjects with myeloproliferative neoplasm (MPN)-associated myelofibrosis and anemia with or without RBC transfusion dependence.

S. Verstovsek, T. Gerike, R. Gale, 2018 .

Phase-2 Study of Sotatercept (ACE-011) in Myeloproliferative Neoplasm-Associated Myelofibrosis and Anemia

H. Kantarjian, S. Verstovsek, E. Jabbour, 2016 .

Pacritinib is a potent ACVR1 inhibitor with significant anemia benefit in patients with myelofibrosis

S. Verstovsek, J. Mascarenhas, A. Gerds, 2022, Blood advances.

Final Results of a Phase 2 Study of Sotatercept (ACE-011) for Anemia of MPN-Associated Myelofibrosis

Z. Estrov, M. Andreeff, H. Kantarjian, 2021, Blood.

Fedratinib Induces Spleen Responses and Reduces Symptom Burden as First-line or Salvage Therapy in Patients with Myeloproliferative Neoplasm-Associated Intermediate- or High-Risk Myelofibrosis (MF) and Low Platelet Counts

S. Verstovsek, T. Gerike, R. Mesa, 2019, Clinical Lymphoma, Myeloma & Leukemia.

P1037: DOES EARLY INTERVENTION IN MYELOFIBROSIS IMPACT OUTCOMES? A POOLED ANALYSIS OF THE COMFORT I AND II STUDIES

S. Verstovsek, A. Vannucchi, J. Kiladjian, 2021, HemaSphere.

Long-term survival in patients treated with ruxolitinib for myelofibrosis: COMFORT-I and -II pooled analyses

Francisco Cervantes, Jason Gotlib, Alessandro M. Vannucchi, 2017, Journal of Hematology & Oncology.

The Impact of Pacritinib on Myelofibrosis Symptoms in Patients with Moderate and Severe Thrombocytopenia: A Retrospective Analysis of Patients in the Persist-2 Study

S. Verstovsek, R. Mesa, A. Vannucchi, 2021, Blood.

MPN-145 Retrospective Analysis of Anemia Benefit of Pacritinib From the PERSIST-2 Trial.

S. Verstovsek, R. Mesa, C. Harrison, 2022, Clinical Lymphoma, Myeloma & Leukemia.

Myeloproliferative Neoplasms, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology.

K. Gregory, Hema M Sundar, S. Verstovsek, 2016, Journal of the National Comprehensive Cancer Network : JNCCN.

A Phase II Study of Low-Dose Pomalidomide (0.5mg/day) and Prednisone Combination Therapy in Patients with Myelofibrosis and Significant Anemia

H. Kantarjian, J. Cortes, S. Verstovsek, 2012 .

Outcome Of Patients (pts) With Myelofibrosis (MF) After Ruxolutinib (Rux) Therapy

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2013 .

Characteristics and Clinical Outcomes of Patients with Acute Lymphoblastic Leukemia with KMT2A (MLL) Rearrangement

M. Konopleva, Z. Estrov, H. Kantarjian, 2019, Blood.

Chronic myeloid leukemia among patients with a history of prior malignancies: A tale of dual survivorship

Z. Estrov, H. Kantarjian, G. Garcia-Manero, 2017, Cancer.

Patients with Chronic Myeloid Leukemia with Variant Philadelphia Chromosome (Ph) Translocations Have a Similar Outcome as Those with Classic Ph When Treated with Imatinib or 2nd Generation TKI

Z. Estrov, H. Kantarjian, J. Cortes, 2008 .

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2013, Clinical lymphoma, myeloma & leukemia.

chronic myelogenous leukemia significance of deletions of derivative chromosome 9 in patients with Imatinib mesylate therapy may overcome the poor prognostic

H. Kantarjian, A. Quintás-Cardama, S. Verstovsek, 2013 .

Ruxolitinib for myelofibrosis: from 'palliation' to prolongation of survival.

S. Verstovsek, 2013, Oncology.

A Randomized Open-Label, Phase 3 Study to Evaluate Imetelstat Versus Best Available Therapy (BAT) in Patients with Intermediate-2 or High-Risk Myelofibrosis (MF) Refractory to Janus Kinase (JAK) Inhibitor

S. Verstovsek, R. Mesa, A. Vannucchi, 2020 .

Results of a prospective, randomized, open-label phase 3 study of ruxolitinib (RUX) in polycythemia vera (PV) patients resistant to or intolerant of hydroxyurea (HU): the RESPONSE trial

M. Griesshammer, S. Verstovsek, R. Mesa, 2014 .

Early intervention in myelofibrosis and impact on outcomes: A pooled analysis of the COMFORT‐I and COMFORT‐II studies

S. Verstovsek, A. Vannucchi, J. Kiladjian, 2023, Cancer.

Sustained‐release ruxolitinib: Findings from a phase 1 study in healthy subjects and a phase 2 study in patients with myelofibrosis

S. Verstovsek, Xuejun Chen, S. Yeleswaram, 2018, Hematological oncology.

Phase II evaluation of IPI-926, an oral Hedgehog inhibitor, in patients with myelofibrosi s

H. Kantarjian, S. Verstovsek, K. Newberry, 2015 .

A Pooled Overall Survival Analysis of The COMFORT Studies: 2 Randomized Phase 3 Trials of Ruxolitinib For The Treatment of Myelofibrosis

S. Verstovsek, R. Mesa, G. Barosi, 2013 .

Long-Term Outcomes Of Ruxolitinib Therapy In Patients With Myelofibrosis: 3-Year Update From COMFORT-I

J. Dipersio, M. Arcasoy, H. Kantarjian, 2013 .

Efficacy, Hematologic Effects, and Dose of Ruxolitinib in Myelofibrosis Patients with Low Starting Platelet Counts (50–100 × 109/L): A Comparison to Patients with Normal or High Starting Platelet Counts

H. Kantarjian, S. Verstovsek, R. Paquette, 2012 .

Preliminary safety and efficacy of ruxolitinib in patients (pts) with primary and secondary myelofibrosis (MF) with platelet counts (PC) of 50-100x109/L.

H. Kantarjian, S. Verstovsek, M. Talpaz, 2012 .

MK-0457, a Novel Multikinase Inhibitor, Is Active in Patients with Chronic Myeloid Leukemia (CML) and Acute Lymphocytic Leukemia (ALL) with the T315I BCR-ABL Resistance Mutation and Patients with Refractory JAK-2 Positive Myeloproliferative Diseases (MPD).

D. Bergstrom, H. Kantarjian, J. Cortes, 2006 .

Updated results from the phase II study of hyper-CVAD in combination with ofatumumab as frontline therapy for adults with CD20 positive (CD20+) acute lymphoblastic leukemia (ALL).

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2016 .

Relationship Between Ruxolitinib Dose and Improvements in Spleen Volume and Symptoms in Patients With Myelofibrosis: Results From COMFORT-I

H. Kantarjian, S. Verstovsek, R. Mesa, 2013 .

Management of Cytopenias With Ruxolitinib Treatment in Patients With Myelofibrosis

A. Quintás-Cardama, S. Verstovsek, R. Mesa, 2013 .

Improvement in Weight and Total Cholesterol and Their Association with Survival in Ruxolitinib-Treated Patients with Myelofibrosis From COMFORT-I

S. Verstovsek, R. Mesa, J. Mascarenhas, 2012 .

Clinical Benefits of Ruxolitinib Therapy in Myelofibrosis Patients with Varying Degrees of Splenomegaly and Symptoms

H. Kantarjian, S. Verstovsek, R. Mesa, 2012 .

Expand: a Phase 1b, Open-Label, Dose-Finding Study of Ruxolitinib in Patients with Myelofibrosis and Baseline Platelet Counts Between 50 × 109/L and 99 × 109/L

S. Verstovsek, G. Barosi, A. Vannucchi, 2012 .

Adverse events (AEs) and the return of myelofibrosis (MF)-related symptoms after interruption or discontinuation of ruxolitinib (RUX) therapy.

J. Dipersio, M. Arcasoy, H. Kantarjian, 2012 .

A Pooled Overall Survival (OS) Analysis of 5-Year Data from the COMFORT-I and COMFORT-II Trials of Ruxolitinib for the Treatment of Myelofibrosis (MF)

S. Verstovsek, R. Mesa, A. Vannucchi, 2016 .

Adapt ive Randomized Study of Idarubic in and Cytarabine Versus Troxaci tabine and Cytarabine Versus Troxaci tabine and Idarubic in in Untreated Pat ients 50 Years or Older With Adverse Karyotype Acute Myelo id Leukemia

D. Berry, E. Estey, J. Wathen, 2003 .

Ten-year follow up of patients with newly diagnosed chronic myeloid leukemia in chronic phase treated with 400 mg or 800 mg of imatinib daily.

H. Kantarjian, J. Cortes, S. Verstovsek, 2014 .

A Phase I Trial of AT9283, a Multitargeted Kinase Inhibitor, in Patients with Refractory Hematological Malignancies.

H. Kantarjian, J. Cortes, S. Verstovsek, 2007 .

Long term follow-up of frontline dasatinib in patients (pts) with early chronic phase chronic myeloid leukemia (CML-CP).

Z. Estrov, H. Kantarjian, J. Cortes, 2016 .

Doxorubicin-induced DNA degradation in murine thymocytes.

M. J. Ehrke, S. Verstovsek, G. Zaleskis, 1994, Molecular pharmacology.

S. Verstovsek, R. Mesa, M. Talpaz, 2019, Blood.

Fedratinib Induces Spleen Responses in Patients with Myeloproliferative Neoplasm (MPN)-Associated Intermediate- or High-Risk Myelofibrosis (MF) Resistant or Intolerant to Ruxolitinib: An Updated Analysis of the Phase II JAKARTA2 Study

S. Verstovsek, T. Gerike, R. Mesa, 2019, Clinical Lymphoma Myeloma and Leukemia.

Clinicopathologic Correlates and Natural History of Atypical Chronic Myeloid Leukemia

M. Konopleva, Z. Estrov, H. Kantarjian, 2020, bioRxiv.

Blockade of adaptive defensive changes in cholesterol uptake and synthesis in AML by the addition of pravastatin to idarubicin + high-dose Ara-C: a phase 1 study.

E. Estey, Z. Estrov, F. Appelbaum, 2005, Blood.

EXABS-164-MPN Novel Therapeutics in Development for Myelofibrosis.

S. Verstovsek, H. Chifotides, 2022, Clinical lymphoma, myeloma & leukemia.

Ruxolitinib or Dasatinib in Combination with Chemotherapy for Patients with Relapsed/Refractory Philadelphia (Ph)-like Acute Lymphoblastic Leukemia: A Phase I-II Trial

C. Mullighan, M. Konopleva, H. Kantarjian, 2017 .

Clinical Significance of Deeper Molecular Responses with Four Modalities of Tyrosine Kinase Inhibitors As Frontline Therapy for Chronic Myeloid Leukemia

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2012 .

Symptomatic benefit of momelotinib in patients with myelofibrosis: Results from the SIMPLIFY phase III studies

A. Mead, S. Verstovsek, R. Donahue, 2023, Cancer medicine.

BMS-911543, A Selective JAK2 Inhibitor: A Multicenter Phase 1/2a Study In Myelofibrosis

H. Kantarjian, S. Verstovsek, A. Roberts, 2013 .

Higher red blood cell distribution width predicts thrombosis risk in primary and secondary myelofibrosis

S. Verstovsek, H. Holik, M. Lucijanić, 2021, Annals of Hematology.

Long-Term Effects of Ruxolitinib on Bone Marrow Morphology in Patients With Myelofibrosis and Comparison to Best Available Therapy

H. Kantarjian, J. Cortes, S. Verstovsek, 2014 .

Therapeutic Potential of JAK2 Inhibitors

S. Verstovsek, 2013 .

Secondary solid tumors and lymphoma in patients with essential thrombocythemia and polycythemia vera – single center experience

Z. Estrov, H. Kantarjian, S. Verstovsek, 2016, Leukemia & lymphoma.

Interactions of Key Hematological Parameters with Red Cell Distribution Width (RDW) Are Associated with Incidence of Thromboembolic Events (TEs) in Polycythemia Vera (PV) Patients: A Machine Learning Study (PV-AIM)

S. Verstovsek, F. Heidel, K. Bryan, 2020 .

Phase I/II study of the combination of 5-azacytidine(5-AC), all-trans retinoic acid (ATRA) and valproic Acid (VPA) in patients with myelodysplastic syndrome (MDS) and leukemia.

Z. Estrov, H. Kantarjian, G. Garcia-Manero, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II Study of Cladribine, Idarubicin, and Cytarabine (araC) in Patients with Acute Myeloid Leukemia (AML)

M. Konopleva, Z. Estrov, H. Kantarjian, 2015 .

Systemic Mastocytosis Patient Experience from Mast Cell Connect, the First Patient-Reported Registry for Mastocytosis

S. Verstovsek, A. Boral, T. George, 2016 .

Serologic versus molecular testing for screening for hepatitis C virus infection in patients with hematologic malignancies

S. Verstovsek, R. Orlowski, H. Torres, 2022, Medicine.

Clinical Activity in a Phase 1 Study of Blu-285, a Potent, Highly-Selective Inhibitor of KIT D816V in Advanced Systemic Mastocytosis (AdvSM)

S. Verstovsek, M. Deininger, D. DeAngelo, 2017 .

Preliminary Safety and Clinical Activity in a Phase 1 Study of Blu-285, a Potent, Highly-Selective Inhibitor of KIT D816V in Advanced Systemic Mastocytosis (SM)

S. Verstovsek, M. Deininger, D. DeAngelo, 2016 .

Safety and efficacy of avapritinib in advanced systemic mastocytosis: the phase 1 EXPLORER trial

S. Verstovsek, M. Deininger, T. George, 2021, Nature Medicine.

A phase 2 study of brentuximab vedotin in patients with CD30-positive advanced systemic mastocytosis.

S. Verstovsek, T. George, J. Gotlib, 2019, Blood advances.

chronic lymphocytic leukemia Transient down-modulation of CD20 by rituximab in patients with

H. Kantarjian, S. Verstovsek, M. Keating, 2013 .

Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Commonly Presents in the Setting of Prior or Concomitant Hematologic Malignancies (PCHM): Patient Characteristics and Outcomes in the Rapidly Evolving Modern Targeted Therapy Era

Hannah C. Beird, M. Konopleva, H. Kantarjian, 2019, Blood.

Long-Term Outcome for De Novo or Minimally Treated Burkitt-Type Lymphoma/Leukemia (BL/B-ALL) After Therapy with Hyper-CVAD and Rituximab

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2010 .

Bone marrow mast cell burden and serum tryptase level as markers of response in patients with systemic mastocytosis

H. Kantarjian, J. Cortes, M. Sever, 2013, Leukemia & lymphoma.

The Effect of Ruxolitinib on White Blood Cell Counts in Patients with Polycythemia Vera: Results from the RESPONSE Trial

M. Griesshammer, S. Verstovsek, A. Vannucchi, 2015 .

Quality and cost comparison of powered versus manual bone marrow biopsy devices in patients with myelofibrosis

S. Verstovsek, C. Bueso-Ramos, N. Short, 2017, Leukemia & lymphoma.

The organic arsenic derivative GMZ27 induces PML-RARα-independent apoptosis in myeloid leukemia cells.

M. Andreeff, H. Kantarjian, A. Quintás-Cardama, 2012, Anticancer research.

Phase I Clinical Trial of CK0801 (cord blood regulatory T cells) in Patients with Bone Marrow Failure Syndrome (BMF) Including Aplastic Anemia, Myelodysplasia and Myelofibrosis

P. Hari, S. Parmar, S. Verstovsek, 2019, Blood.

Combined Cyclophosphamide, Fludarabine, Alemtuzumab, and Rituximab (CFAR), an Active Frontline Regimen for High-Risk Patients with CLL.

Z. Estrov, G. Garcia-Manero, S. Verstovsek, 2007 .

Durable Responses with the JAK1/ JAK2 Inhibitor, INCB018424, In Patients with Polycythemia Vera (PV) and Essential Thrombocythemia (ET) Refractory or Intolerant to Hydroxyurea (HU)

M. Cazzola, T. Barbui, H. Kantarjian, 2010 .

Memory Impairment in Chronic Phase (CP) Chronic Myeloid Leukemia (CML) Patients (pts) Treated with Dasatinib Tyrosine Kinase Inhibitor (TKI) Therapy

E. Burton, H. Kantarjian, J. Cortes, 2011 .

The role of therapy in the outcome of patients with myelofibrosis

Z. Estrov, H. Kantarjian, S. Verstovsek, 2023, Cancer.

Hypomethylation Dynamics Following Decitabine Therapy in Chronic Myelogenous Leukemia.

J. Issa, J. Jelinek, H. Kantarjian, 2004 .

Momelotinib's Spleen, Symptom and Anemia Efficacy Is Maintained in Intermediate/High Risk Myelofibrosis Patients with Thrombocytopenia

S. Verstovsek, R. Donahue, R. Mesa, 2020 .

Long-Term Efficacy and Safety Results From a Phase II Study of Ruxolitinib in Patients with Polycythemia Vera

M. Cazzola, T. Barbui, H. Kantarjian, 2012 .

Therapy with the Histone Deacetylase Inhibitor Sb939 for Patients with Myelofibrosis

Z. Estrov, H. Kantarjian, J. Cortes, 2011 .

Acute lymphoblastic leukemia arising in post-polycythemic myelofibrosis: a rare entity

Z. Estrov, H. Kantarjian, S. Verstovsek, 2012, Leukemia & lymphoma.

Significant Activity of the JAK2 Inhibitor, INCB018424 in Patients with Secondary, Post-Myeloproliferative Disorder (MPD) Acute Myeloid Leukemia (sAML): Results of An Exploratory Phase II Study.

Z. Estrov, H. Kantarjian, S. Verstovsek, 2009 .

Phase I Study of AVE9633, an AntiCD33-Maytansinoid Immunoconjugate, Administered as an Intravenous Infusion in Patients with Refractory/Relapsed CD33-Positive Acute Myeloid Leukemia (AML).

S. Verstovsek, F. Ravandi, D. DeAngelo, 2006 .

Results of COMFORT-I, a randomized double-blind phase III trial of JAK 1/2 inhibitor INCB18424 (424) versus placebo (PB) for patients with myelofibrosis (MF).

J. Dipersio, H. Kantarjian, S. Verstovsek, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II study of SB1518, an orally available novel JAK2 inhibitor, in patients with myelofibrosis.

H. Deeg, Z. Estrov, H. Kantarjian, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

RESPONSE: A randomized, open label, phase III study of INC424 in polycythemia vera (PV) patients resistant to or intolerant of hydroxyurea (HU).

S. Verstovsek, R. Huber, W. Garrett, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Association of Myelofibrosis Phenotypes with Clinical Manifestations, Molecular Profiles, and Treatments

S. Verstovsek, P. Bose, H. Chifotides, 2023, Cancers.

Ruxolitinib: the first agent approved for myelofibrosis.

S. Verstovsek, 2012, Clinical advances in hematology & oncology : H&O.

Long-term Results From a Phase II Open-label Study of Ruxolitinib in Patients With Essential Thrombocythemia Refractory to or Intolerant of Hydroxyurea

M. Cazzola, T. Barbui, Haifeng Zhang, 2014 .

Additional Chromosomal Abnormalities in Philadelphia Chromosome-Negative Metaphases Appearing during Therapy with Imatinib, Dasatinib, Nilotinib and Ponatinib in Patients with Newly Diagnosed Chronic Myeloid Leukemia

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2015 .

Phase I Studies

Farhad, M. Ratain, R. Larson, 2022 .

Cladribine Combined with Idarubicin and Ara-C (CLIA) As a Frontline and Salvage Treatment for Young Patients (≤65 yrs) with Acute Myeloid Leukemia

M. Konopleva, Z. Estrov, H. Kantarjian, 2016 .

A Phase 3 Study of the Hepcidin Mimetic Rusfertide (PTG-300) in Patients with Polycythemia Vera

S. Verstovsek, R. Hoffman, N. Pemmaraju, 2021, Blood.

MK-0457 Is a Novel Aurora Kinase and Janus Kinase 2 (JAK2) Inhibitor with Activity in Transformed JAK2-Positive Myeloproliferative Disease (MPD).

D. Bergstrom, M. Andreeff, H. Kantarjian, 2006 .

PEG-Intron for Myeloproliferative Diseases: An Update of Ongoing Phase II Study.

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2004 .

Prognostic significance of Tie‐1 protein expression in patients with early chronic phase chronic myeloid leukemia

H. Kantarjian, J. Cortes, T. Manshouri, 2002, Cancer.

High Expression of the Receptor Tyrosine Kinase Tie-1 in Acute Myeloid Leukemia and Myelodysplastic Syndrome

H. Kantarjian, T. Manshouri, S. Verstovsek, 2001, Leukemia & lymphoma.

Treatment of essential thrombocytopenia patients intolerant/ resistant to hydroxyurea: A physician survey.

S. Verstovsek, J. Mascarenhas, B. Gagnon, 2017 .

Telomerase activity is not a prognostic factor in chronic lymphocytic leukemia.

H. Kantarjian, S. Verstovsek, M. Keating, 2004, Leukemia research.

Will Imitanib Be Useful for Patients with Polycythemia Vera

W. Vainchenker, J. Cortes, S. Verstovsek, 2005 .

Ruxolitinib (RUX) in Combination with 5-Azacytidine (AZA) As Therapy for Patients (pts) with Myelofibrosis (MF)

Z. Estrov, H. Kantarjian, G. Garcia-Manero, 2016 .

Altered T-cell subset repertoire affects treatment outcome of patients with myelofibrosis

Z. Estrov, T. Manshouri, S. Verstovsek, 2020, Haematologica.

Treatment of systemic mastocytosis with denileukin diftitox

H. Kantarjian, A. Quintás-Cardama, S. Verstovsek, 2007, American journal of hematology.

MPN-238 Single-Cell RNA Profiling of Myelofibrosis Patients Reveals Pelabresib-Induced Decrease of Megakaryocytic Progenitors and Normalization of CD4+ T Cells in Peripheral Blood.

A. Mead, S. Verstovsek, N. Haradhvala, 2022, Clinical lymphoma, myeloma & leukemia.

MPN-328: Pelabresib (CPI-0610) Improved Anemia Associated with Myelofibrosis: Interim Results from the Ongoing MANIFEST Phase 2 Study

S. Verstovsek, R. Hoffman, M. Talpaz, 2021 .

Avapritinib for Systemic Mastocytosis

S. Verstovsek, P. Bose, 2021, Expert review of hematology.

Associations Between Improvements in Myelofibrosis (MF) Symptoms and Quality of Life Measures with Splenomegaly Reduction in COMFORT-I: A Randomized, Double-Blind, Phase III Trial of the JAK1 and JAK2 Inhibitor Ruxolitinib Versus Placebo in Patients with MF,

A. Shields, J. Dipersio, H. Kantarjian, 2011 .

Clinical Outcomes with Hypomethylating Agents in Patients with Myelodysplastic Syndrome/Myeloproliferative Neoplasm with Ring Sideroblasts and Thrombocytosis (MDS/MPN-RS-T); A Case Series

H. Kantarjian, G. Garcia-Manero, S. Verstovsek, 2020 .

Optimizing Dose Titration Of Ruxolitinib: The COMFORT-I Experience

S. Verstovsek, R. Mesa, R. Komrokji, 2013 .

Effects Of Five-Years Of Ruxolitinib Therapy On Bone Marrow Morphology In Patients With Myelofibrosis and Comparison With Best Available Therapy

H. Kantarjian, J. Cortes, S. Verstovsek, 2013 .

Effects Of Ruxolitinib Therapy On Megakaryocyte Morphology and Inflammatory Bone Marrow Reaction In Patients With Myelofibrosis

H. Kantarjian, J. Cortes, S. Verstovsek, 2013 .

Pacritinib, a Dual JAK2/FLT3 Inhibitor: An Integrated Efficacy and Safety Analysis Of Phase II Trial Data In Patients With Primary and Secondary Myelofibrosis (MF) and Platelet Counts ≤100,000/µl

S. Verstovsek, R. Mesa, J. Dean, 2013 .

Genes Involved in Maintaining the Bone Marrow Stroma Are Dysregulated in Patients with Myelofibrosis: Lenalidomide Treatment Up-regulates SOCS3.

T. Manshouri, S. Verstovsek, K. Newberry, 2014, Anticancer research.

A phase II study of cloretazine (VNP40101M), a novel sulfonylhydrazine alkylating agent, in patients with very high risk relapsed acute myeloid leukemia.

H. Kantarjian, S. Verstovsek, J. Karp, 2006, Leukemia research.

STAT3 Activates the Pentraxin 3 Gene in Chronic Lymphocytic Leukemia Cells

Z. Estrov, D. Harris, T. Manshouri, 2022, The Journal of Immunology.

Cladribine Combined with Idarubicin and High-Dose AraC (CLIA2) As a Frontline and Salvage Treatment for Young Patients (≤65 yrs) with Acute Myeloid Leukemia

M. Konopleva, Z. Estrov, H. Kantarjian, 2016, Blood.

Long non-coding RNAs in primary myelofibrosis: the dark matter in hematopoietic progenitor cells?

G. Calin, S. Verstovsek, K. Roosbroeck, 2015, Leukemia and Lymphoma.

Ten years of treatment with ruxolitinib for myelofibrosis: a review of safety

S. Verstovsek, R. Mesa, J. Mascarenhas, 2023, Journal of Hematology & Oncology.

High Rates of Molecular Response After Long-Term Follow-up of Patients with Advanced Essential Thrombocythemia (ET) or Polycythemia Vera (PV) Treated with Pegylated Interferon-ALFA-2A (PEG-IFN-α-2A; PEGASYS)

O. Kilpivaara, R. Levine, H. Kantarjian, 2010 .

Myelodysplastic/ Myeloproliferative Neoplasms-Unclassifiable (MDS/MPN-U) with Isolated Isochromosome 17q Represents a Distinct Clinico-Biologic Subset: A Multi-institutional Collaborative Study from the Bone Marrow Pathology Group

K. Do, P. Cin, A. Bagg, 2021, Modern Pathology.

Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate.

M. Andreeff, H. Kantarjian, G. Garcia-Manero, 2004, Blood.

Primary Analysis Results from an Open-Label Phase II Study of INCB039110, a Selective JAK1 Inhibitor, in Patients with Myelofibrosis

S. Verstovsek, R. Hoffman, R. Paquette, 2014 .

Phase I Study Of LY2784544, a JAK2 Selective Inhibitor, In Patients With Myelofibrosis (MF), Polycythemia Vera (PV), and Essential Thrombocythemia (ET)

M. Salama, S. Verstovsek, R. Mesa, 2013 .

The role of cytogenetic abnormalities as a prognostic marker in primary myelofibrosis: applicability at the time of diagnosis and later during disease course

H. Kantarjian, J. Cortes, S. Verstovsek, 2009 .

Clinicopathologic spectrum of myeloid neoplasms with concurrent myeloproliferative neoplasm driver mutations and SRSF2 mutations

S. Verstovsek, M. Routbort, K. Patel, 2022, Modern Pathology.

Safety and efficacy of zinpentraxin alfa as monotherapy or in combination with ruxolitinib in myelofibrosis: stage I of a phase II trial

T. Manshouri, S. Verstovsek, K. Trunzer, 2023, Haematologica.

Hyper-CVAD and Rituximab for De Novo Burkitt Lymphoma/Leukemia

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2011 .

Results from ongoing phase 1/2 clinical trial of tagraxofusp (SL-401) in patients with intermediate or high risk relapsed/refractory myelofibrosis.

S. Verstovsek, C. Brooks, M. Talpaz, 2019, Journal of Clinical Oncology.

Results from Ongoing Phase 1/2 Clinical Trial of Tagraxofusp (SL-401) in Patients with Intermediate or High Risk Relapsed/Refractory Myelofibrosis

S. Verstovsek, C. Brooks, M. Talpaz, 2018, Blood.

Results from ongoing phase 1/2 clinical trial of tagraxofusp (SL-401) in patients with relapsed/refractory chronic myelomonocytic leukemia (CMML).

S. Verstovsek, C. Brooks, M. Talpaz, 2019, Journal of Clinical Oncology.

Do We Need to Re-Define Accelerated Phase of Myelofibrosis? Correlation between Blast Percentage in Myelofibrosis and Outcomes

H. Kantarjian, J. Cortes, S. Verstovsek, 2017 .

Identifying Patients with Polycythemia Vera at Risk of Thrombosis after Hydroxyurea Initiation: The Polycythemia Vera—Advanced Integrated Models (PV-AIM) Project

S. Verstovsek, F. Heidel, V. De Stefano, 2023, Biomedicines.

Outcome After Failure to Second Generation Thyrosine Kinase Inhibitors(TKI) Treatment as Frontline Therapy for Patients with Chronic Myeloid Leukemia (CML) In Chronic Phase(CP).

M. Konopleva, E. Burton, H. Kantarjian, 2010 .

FIGHT-203, an Ongoing Phase 2 Study of Pemigatinib in Patients With Myeloid/Lymphoid Neoplasms (MLNs) With Fibroblast Growth Factor Receptor 1 (FGFR1) Rearrangement (MLNFGFR1): A Focus on Centrally Reviewed Clinical and Cytogenetic Responses in Previously Treated Patients

S. Verstovsek, A. Vannucchi, J. Gotlib, 2022, Blood.

A Phase 2 Study of Pemigatinib (FIGHT-203; INCB054828) in Patients with Myeloid/Lymphoid Neoplasms (MLNs) with Fibroblast Growth Factor Receptor 1 (FGFR1) Rearrangement (MLN FGFR1)

S. Verstovsek, T. George, A. Vannucchi, 2021, Blood.

A phase II study of cpi-0610, a bromodomain and extraterminal protein inhibitor (BETi) alone or with ruxolitinib (RUX), in patients with myelofibrosis (MF).

P. Trojer, S. Verstovsek, R. Hoffman, 2019, Journal of Clinical Oncology.

Phase I study of BP1001 (Liposomal Grb2 Antisense) in patients with hematologic malignancies.

M. Konopleva, M. Andreeff, G. Garcia-Manero, 2016 .

Efficacy and safety of pegylated interferon alpha-2a in patients with essential thrombocythemia (ET) and polycythemia vera (PV): results of a phase 2 study after a 7-year median follow-up

M. Konopleva, Z. Estrov, H. Kantarjian, 2017, The Lancet. Haematology.

Momelotinib long-term safety and survival in myelofibrosis: integrated analysis of phase 3 randomized controlled trials

S. Verstovsek, A. Vannucchi, C. Harrison, 2023, Blood advances.

Paroxysmal nocturnal hemoglobinuria is not a cause of anemia in patients with myelofibrosis

S. Verstovsek, J. Jorgensen, A. Nazha, 2014, Leukemia & lymphoma.

Phase 1/2 Study of SB1518, a Novel JAK2/FLT3 Inhibitor, In the Treatment of Primary Myelofibrosis

H. Deeg, Z. Estrov, H. Kantarjian, 2010 .

Journal of Experimental Pharmacology Dovepress Comprehensive Kinase Profile of Pacritinib, a Nonmyelosuppressive Janus Kinase 2 Inhibitor

Haiching Ma, S. Verstovsek, R. Mesa, 2022 .

Fedratinib (FEDR) in myelofibrosis (MF) patients previously treated with ruxolitinib (RUX): A reanalysis of the JAKARTA-2 study.

S. Verstovsek, T. Gerike, R. Mesa, 2019, Journal of Clinical Oncology.

Practical Measures of Clinical Benefit with Ruxolitinib Therapy: An Exploratory Analysis of COMFORT-I

S. Verstovsek, R. Mesa, Carole B. Miller, 2014 .

Experience with everolimus (RAD001), an oral mammalian target of rapamycin inhibitor, in patients with systemic mastocytosis

H. Kantarjian, J. Cortes, S. Verstovsek, 2010, Leukemia & lymphoma.

Mechanistic Basis and Efficacy of Targeting β-Catenin-TCF7L2-JMJD6-MYC Axis to Overcome Resistance to BET Inhibitors

K. Bhalla, T. Manshouri, S. Verstovsek, 2019, Blood.

Final Results of Phase 2 Clinical Trial of LCL161, a Novel Oral SMAC Mimetic/IAP Antagonist, for Patients with Intermediate to High Risk Myelofibrosis

M. Konopleva, Z. Estrov, H. Kantarjian, 2019, Blood.

MANIFEST, a Phase 2 Study of CPI-0610, a Bromodomain and Extraterminal Domain Inhibitor (BETi), As Monotherapy or "Add-on" to Ruxolitinib, in Patients with Refractory or Intolerant Advanced Myelofibrosis

B. Leber, P. Trojer, S. Verstovsek, 2019, Blood.

Computed tomographic scan of the chest, latex agglutination test and plasma (1AE3)-beta-D-glucan assay in early diagnosis of invasive pulmonary aspergillosis: a prospective study of 215 patients

J. Jelinek, H. Kantarjian, Y. Kanda, 1994 .

PRM-151 in Myelofibrosis: Durable Efficacy and Safety at 72 Weeks

M. Salama, H. Kantarjian, S. Verstovsek, 2015 .

Imatinib mesylate dose escalation is associated with durable responses in patients with chronic myeloid leukemia after cytogenetic failure on standard-dose imatinib therapy.

H. Kantarjian, G. Garcia-Manero, S. Verstovsek, 2009 .

Imatinib mesylate dose escalation is associated with durable responses in patients with chronic myeloid leukemia after cytogenetic failure on standard-dose imatinib therapy.

B. Barlogie, M. Dimopoulos, P. Sonneveld, 2009, Blood.

Result of high-dose imatinib mesylate in patients with Philadelphia chromosome-positive chronic myeloid leukemia after failure of interferon-alpha.

H. Kantarjian, G. Garcia-Manero, S. Verstovsek, 2003, Blood.

A Randomized Trial of High-Dose (HD) Imatinib Mesylate (IM) with or without Peg-Interferon (PEG-IFN) and GM-CSF as Frontline Therapy for Patients with Chronic Myeloid Leukemia (CML) in Early Chronic Phase (CP).

Z. Estrov, M. Andreeff, H. Kantarjian, 2005 .

Chronic myeloid leukemia (CML) with P190 BCR-ABL: analysis of characteristics, outcomes, and prognostic significance.

H. Kantarjian, S. Verstovsek, G. Borthakur, 2009, Blood.

Plausibility of Delaying Induction Therapy in Untreated AML.

P. Thall, E. Estey, H. Kantarjian, 2004 .

The role of cytogenetic abnormalities as a prognostic marker in primary myelofibrosis: applicability at the time of diagnosis and later during disease course.

H. Kantarjian, J. Cortes, S. Verstovsek, 2009, Blood.

Effective treatment of acute promyelocytic leukemia with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin.

E. Estey, Z. Estrov, H. Kantarjian, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Targeting nuclear β-catenin as therapy for post-myeloproliferative neoplasm secondary AML

P. Qiu, K. Rajapakshe, C. Coarfa, 2018, Leukemia.

Molecular analysis of patients with polycythemia vera or essential thrombocythemia receiving pegylated interferon α-2a.

O. Abdel-Wahab, Z. Estrov, D. Harris, 2013, Blood.

Phase 2 study of CEP-701, an orally available JAK2 inhibitor, in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis.

Z. Estrov, H. Kantarjian, G. Garcia-Manero, 2010, Blood.

Mutations and promoter methylation status of NPM1 in myeloproliferative disorders

S. Chavali, A. Mahajan, D. Bharadwaj, 2000 .

Aberrant myeloid maturation identified by flow cytometry in primary myelofibrosis.

S. Verstovsek, J. Jorgensen, P. Lin, 2010, American journal of clinical pathology.

A. Órfão, H. Kluin-Nelemans, S. Verstovsek, 2013, Blood.

Specific anti-EL4-lymphoma immunity in mice cured 2 years earlier with doxorubicin and interleukin-2

S. Verstovsek, G. Zaleskis, E. Mihich, 1996, Cancer Immunology, Immunotherapy.

Phase I study of sorafenib in patients with refractory or relapsed acute leukemias

M. Konopleva, M. Andreeff, H. Kantarjian, 2011, Haematologica.

Chronic myelogenous leukemia in patients with MPL or JAK2 mutation‐positive myeloproliferative neoplasm

S. Verstovsek, L. Medeiros, W. Wang, 2015, International journal of laboratory hematology.

Bone marrow stroma-secreted cytokines protect JAK2(V617F)-mutated cells from the effects of a JAK2 inhibitor.

Z. Estrov, D. Harris, H. Kantarjian, 2011, Cancer research.

Bone Marrow Stroma – Secreted Cytokines Protect JAK2 V617F -Mutated Cells from the Effects of a JAK2 Inhibitor

C. Creighton, Z. Estrov, D. Harris, 2011 .

Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis.

Z. Estrov, H. Kantarjian, S. Verstovsek, 2010, The New England journal of medicine.

Imatinib mesylate dose escalation is associated with durable responses in patients with chronic myeloid leukemia after cytogenetic failure on standard-dose imatinib therapy.

H. Kantarjian, G. Garcia-Manero, S. Verstovsek, 2009, Blood.

Long-Term Incidence and Outcome of BCR-ABL Mutations in Patients (pts) with Chronic Myeloid Leukemia (CML) Treated with Imatinib Mesylate - P-Loop Mutations Are Not Associated with Worse Outcome.

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2004 .

Investigational histone deacetylase inhibitors (HDACi) in myeloproliferative neoplasms

S. Verstovsek, P. Bose, 2016, Expert opinion on investigational drugs.

What are RBC-transfusion-dependence and -independence?

K. Döhner, T. Barbui, S. Verstovsek, 2011, Leukemia research.

Ruxolitinib in combination with lenalidomide as therapy for patients with myelofibrosis

H. Kantarjian, J. Cortes, S. Verstovsek, 2015, Haematologica.

Revised response criteria for myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report.

N. Kröger, T. Barbui, S. Verstovsek, 2013, Blood.

Assessing efficacy in myelofibrosis treatment: a focus on JAK inhibition

S. Verstovsek, R. Komrokji, 2012, Expert review of hematology.

Cladribine and low-dose cytarabine alternating with decitabine as front-line therapy for elderly patients with acute myeloid leukaemia: a phase 2 single-arm trial.

M. Konopleva, Z. Estrov, H. Kantarjian, 2018, The Lancet. Haematology.

Markers of iron deficiency in patients with polycythemia vera receiving ruxolitinib or best available therapy.

S. Verstovsek, A. Vannucchi, C. Harrison, 2017, Leukemia research.

Pegylated interferon alfa-2a yields high rates of hematologic and molecular response in patients with advanced essential thrombocythemia and polycythemia vera.

M. Konopleva, Z. Estrov, H. Kantarjian, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I Study of the Akt-Inhibitor Triciribine Phosphate Monohydrate in Patients with Advanced Hematologic Malignancy

H. Kantarjian, G. Garcia-Manero, S. Verstovsek, 2008 .

WP1066, a Novel JAK2 Inhibitor, Suppresses Proliferation and Induces Apoptosis in Erythroid Human Cells Carrying the JAK2 V617F Mutation

Z. Estrov, D. Harris, H. Kantarjian, 2008, Clinical Cancer Research.

Z. Estrov, H. Kantarjian, G. Garcia-Manero, 2008, Blood.

Myelofibrosis-associated complications: pathogenesis, clinical manifestations, and effects on outcomes

S. Verstovsek, K. Vaddi, N. Sarlis, 2014, International journal of general medicine.

Single-Center Experience of Immunosuppressive Therapy with or without Eltrombopag in Patients with Aplastic Anemia

Z. Estrov, H. Kantarjian, G. Garcia-Manero, 2015 .

Tyrosine kinase inhibitors as initial therapy for patients with chronic myeloid leukemia in accelerated phase.

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2014, Clinical lymphoma, myeloma & leukemia.

Chronic myeloid leukemia (CML) with P190 BCR-ABL: analysis of characteristics, outcomes, and prognostic significance.

H. Kantarjian, S. Verstovsek, G. Borthakur, 2009, Blood.

An accurate, simple prognostic model consisting of age, JAK2, CALR, and MPL mutation status for patients with primary myelofibrosis

Z. Estrov, H. Kantarjian, T. Manshouri, 2017, Haematologica.

Pharmacotherapy of polycythemia vera

S. Verstovsek, A. Nazha, Constantine S. Tam, 2013 .

Ruxolitinib: a targeted treatment option for patients with polycythemia vera Blood and Lymphatic Cancer: Targets and Therapy

S. Verstovsek, K. Vaddi, J. Kiladjian, 2016 .

chronic lymphocytic leukemia Transient down-modulation of CD20 by rituximab in patients with

H. Kantarjian, S. Verstovsek, M. Keating, 2013 .

Novel Therapies in Myeloproliferative Neoplasms (MPN): Beyond JAK Inhibitors

S. Verstovsek, N. Pemmaraju, M. Economides, 2019, Current Hematologic Malignancy Reports.

S828 A RANDOMIZED, DOUBLE BLIND PHASE 2 STUDY OF 3 DIFFERENT DOSES OF PRM-151 IN PATIENTS WITH MYELOFIBROSIS WHO WERE PREVIOUSLY TREATED WITH OR INELIGIBLE FOR RUXOLITINIB

S. Verstovsek, M. Wadleigh, R. Mesa, 2019, HemaSphere.

A Phase 2 Study of Cpi-0610, a Bromodomain and Extraterminal (BET) Inhibitor, in Patients with Myelofibrosis (MF)

S. Verstovsek, R. Hoffman, A. Senderowicz, 2018, Blood.

Ruxolitinib-Induced Modulation of Bone Marrow Microenvironment in Patients with Myelofibrosis Is Associated with Inflammatory Cytokine Levels

H. Kantarjian, J. Cortes, S. Verstovsek, 2014 .

5-Azacytidine (AZA) in Combination with Ruxolitinib (RUX) As Therapy for Patients (pts) with Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPNs)

M. Konopleva, Z. Estrov, H. Kantarjian, 2015 .

Clinical development and management of adverse events associated with FGFR inhibitors

S. Verstovsek, V. Subbiah, 2023, Cell reports. Medicine.

P1024: MYLOX-1: A PHASE II STUDY EVALUATING THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND PHARMACODYNAMICS OF ORAL LOXL2 INHIBITOR GB2064 (WITH FOCUS ON BONE MARROW COLLAGEN) IN PATIENTS WITH MYELOFIBROSIS

R. Schlenk, S. Verstovsek, D. Cilloni, 2023, HemaSphere.

Novel and emerging therapies for the treatment of polycythemia vera

S. Verstovsek, R. Komrokji, 2015, Expert review of hematology.

Characteristics and clinical significance of cytogenetic abnormalities in polycythemia vera

S. Verstovsek, C. Bueso-Ramos, Shaoying Li, 2017, Haematologica.

JAK inhibitors for the treatment of myeloproliferative neoplasms and other disorders [version 1; peer review: 2 approved

W. Vainchenker, S. Verstovsek, I. Plo, 2022 .

Changes in bone marrow fibrosis during momelotinib or ruxolitinib therapy do not correlate with efficacy outcomes in patients with myelofibrosis

S. Verstovsek, M. McMullin, J. Kiladjian, 2024, EJHaem.

Phase I Study of the JAK2 V617F Inhibitor, LY2784544, in Patients with Myelofibrosis (MF), Polycythemia Vera (PV), and Essential Thrombocythemia (ET)

S. Verstovsek, R. Mesa, J. Prchal, 2011 .